| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 116 | 2022 | 370 | 10.440 |
Why?
|
| Genome-Wide Association Study | 140 | 2025 | 1765 | 6.000 |
Why?
|
| Genetic Predisposition to Disease | 136 | 2025 | 2474 | 5.930 |
Why?
|
| Polymorphism, Single Nucleotide | 147 | 2025 | 2494 | 5.450 |
Why?
|
| Influenza Vaccines | 60 | 2022 | 173 | 5.290 |
Why?
|
| Influenza A virus | 82 | 2020 | 177 | 5.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 85 | 2023 | 1230 | 3.630 |
Why?
|
| Quantitative Trait Loci | 37 | 2024 | 632 | 3.240 |
Why?
|
| Genetic Linkage | 72 | 2015 | 623 | 2.800 |
Why?
|
| Genetic Variation | 66 | 2023 | 1423 | 2.650 |
Why?
|
| Phenotype | 82 | 2025 | 2578 | 2.590 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 33 | 2016 | 115 | 2.520 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 34 | 2017 | 66 | 2.440 |
Why?
|
| Humans | 580 | 2025 | 96105 | 2.430 |
Why?
|
| Chromosome Mapping | 65 | 2021 | 1083 | 2.340 |
Why?
|
| Genome, Human | 43 | 2025 | 824 | 2.310 |
Why?
|
| Genotype | 88 | 2023 | 1881 | 2.130 |
Why?
|
| Pharmacogenetics | 23 | 2022 | 456 | 2.090 |
Why?
|
| Biological Specimen Banks | 6 | 2022 | 72 | 2.000 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 34 | 2017 | 87 | 1.980 |
Why?
|
| Transcriptome | 18 | 2025 | 769 | 1.970 |
Why?
|
| Electronic Health Records | 18 | 2025 | 372 | 1.790 |
Why?
|
| Models, Genetic | 43 | 2025 | 984 | 1.760 |
Why?
|
| Calpain | 20 | 2006 | 113 | 1.660 |
Why?
|
| Gene Expression Regulation | 26 | 2021 | 2061 | 1.630 |
Why?
|
| Alzheimer Disease | 11 | 2024 | 606 | 1.620 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 34 | 2016 | 83 | 1.600 |
Why?
|
| Alleles | 47 | 2021 | 1157 | 1.550 |
Why?
|
| Quantitative Trait, Heritable | 14 | 2019 | 125 | 1.510 |
Why?
|
| Influenza in Birds | 16 | 2014 | 31 | 1.480 |
Why?
|
| Computational Biology | 22 | 2022 | 586 | 1.460 |
Why?
|
| Pandemics | 10 | 2022 | 880 | 1.460 |
Why?
|
| Eye Diseases | 2 | 2025 | 59 | 1.440 |
Why?
|
| Disease Outbreaks | 31 | 2013 | 157 | 1.430 |
Why?
|
| Global Health | 11 | 2022 | 213 | 1.420 |
Why?
|
| Genetic Association Studies | 11 | 2020 | 301 | 1.360 |
Why?
|
| Databases, Genetic | 18 | 2021 | 284 | 1.350 |
Why?
|
| Population Surveillance | 9 | 2022 | 218 | 1.310 |
Why?
|
| Polymorphism, Genetic | 42 | 2021 | 829 | 1.300 |
Why?
|
| Software | 19 | 2024 | 698 | 1.280 |
Why?
|
| Multifactorial Inheritance | 15 | 2025 | 202 | 1.250 |
Why?
|
| Female | 234 | 2025 | 50028 | 1.180 |
Why?
|
| Genomics | 20 | 2025 | 857 | 1.180 |
Why?
|
| Asthma | 18 | 2025 | 1051 | 1.140 |
Why?
|
| Linkage Disequilibrium | 32 | 2021 | 481 | 1.140 |
Why?
|
| Epidemiological Monitoring | 4 | 2018 | 43 | 1.140 |
Why?
|
| Gene Expression Profiling | 24 | 2021 | 1535 | 1.140 |
Why?
|
| Orthomyxoviridae | 9 | 2019 | 48 | 1.130 |
Why?
|
| Male | 208 | 2025 | 45863 | 1.110 |
Why?
|
| Stuttering | 10 | 2006 | 22 | 1.080 |
Why?
|
| Gene Frequency | 40 | 2021 | 703 | 1.070 |
Why?
|
| Neuraminidase | 21 | 2017 | 47 | 1.060 |
Why?
|
| Pedigree | 48 | 2025 | 982 | 1.030 |
Why?
|
| World Health Organization | 9 | 2019 | 122 | 1.020 |
Why?
|
| DNA Copy Number Variations | 8 | 2021 | 191 | 1.000 |
Why?
|
| Data Interpretation, Statistical | 10 | 2021 | 312 | 0.980 |
Why?
|
| Tourette Syndrome | 8 | 2021 | 24 | 0.970 |
Why?
|
| Adult | 152 | 2025 | 28721 | 0.970 |
Why?
|
| Gene Expression | 14 | 2023 | 1320 | 0.960 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 13 | 2011 | 701 | 0.950 |
Why?
|
| Pharmacogenomic Variants | 5 | 2021 | 44 | 0.940 |
Why?
|
| Genetics, Medical | 3 | 2024 | 51 | 0.910 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 6 | 2021 | 209 | 0.910 |
Why?
|
| Azathioprine | 5 | 2025 | 125 | 0.900 |
Why?
|
| Insulin | 22 | 2017 | 1190 | 0.890 |
Why?
|
| Child | 86 | 2025 | 7625 | 0.870 |
Why?
|
| Disease | 8 | 2021 | 93 | 0.850 |
Why?
|
| Case-Control Studies | 42 | 2025 | 1957 | 0.840 |
Why?
|
| Diabetes Mellitus, Type 1 | 14 | 2021 | 595 | 0.840 |
Why?
|
| Microglia | 1 | 2024 | 124 | 0.830 |
Why?
|
| Awards and Prizes | 1 | 2024 | 37 | 0.820 |
Why?
|
| Breast Neoplasms | 16 | 2020 | 3157 | 0.810 |
Why?
|
| Cytochrome P-450 CYP2D6 | 5 | 2014 | 52 | 0.800 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 4 | 2015 | 4 | 0.790 |
Why?
|
| Nerve Tissue Proteins | 10 | 2017 | 515 | 0.790 |
Why?
|
| Antigens, Viral | 16 | 2017 | 135 | 0.780 |
Why?
|
| Antiviral Agents | 20 | 2014 | 504 | 0.770 |
Why?
|
| Antineoplastic Agents | 16 | 2022 | 2418 | 0.760 |
Why?
|
| Orthomyxoviridae Infections | 16 | 2016 | 57 | 0.760 |
Why?
|
| Gene Dosage | 4 | 2011 | 212 | 0.760 |
Why?
|
| Virus Replication | 18 | 2016 | 326 | 0.750 |
Why?
|
| Haplotypes | 33 | 2025 | 650 | 0.740 |
Why?
|
| Epithelial Cells | 6 | 2021 | 705 | 0.720 |
Why?
|
| Risk Factors | 49 | 2025 | 5961 | 0.720 |
Why?
|
| Influenza B virus | 14 | 2015 | 33 | 0.720 |
Why?
|
| Viral Vaccines | 4 | 2021 | 48 | 0.710 |
Why?
|
| Algorithms | 17 | 2023 | 2015 | 0.710 |
Why?
|
| Lupus Erythematosus, Systemic | 5 | 2025 | 235 | 0.710 |
Why?
|
| Mental Disorders | 6 | 2025 | 463 | 0.690 |
Why?
|
| United States | 52 | 2024 | 7768 | 0.690 |
Why?
|
| Mexican Americans | 15 | 2025 | 70 | 0.690 |
Why?
|
| Genes, Viral | 23 | 2009 | 109 | 0.690 |
Why?
|
| Macrophages | 1 | 2024 | 623 | 0.680 |
Why?
|
| Kidney Tubules | 1 | 2021 | 91 | 0.670 |
Why?
|
| Child, Preschool | 56 | 2021 | 3974 | 0.670 |
Why?
|
| Molecular Sequence Data | 53 | 2014 | 3040 | 0.660 |
Why?
|
| Animals | 98 | 2023 | 28891 | 0.660 |
Why?
|
| Middle Aged | 106 | 2025 | 28368 | 0.650 |
Why?
|
| Genetic Testing | 13 | 2023 | 565 | 0.650 |
Why?
|
| Autistic Disorder | 9 | 2021 | 150 | 0.650 |
Why?
|
| Stress, Mechanical | 1 | 2021 | 261 | 0.650 |
Why?
|
| Reassortant Viruses | 12 | 2015 | 23 | 0.640 |
Why?
|
| Methyltransferases | 5 | 2025 | 213 | 0.640 |
Why?
|
| Genetic Loci | 7 | 2023 | 260 | 0.640 |
Why?
|
| Communicable Disease Control | 2 | 2018 | 56 | 0.640 |
Why?
|
| Lod Score | 17 | 2007 | 153 | 0.640 |
Why?
|
| Mosaicism | 3 | 2025 | 74 | 0.630 |
Why?
|
| Antibodies, Viral | 21 | 2021 | 348 | 0.620 |
Why?
|
| Cisplatin | 10 | 2022 | 611 | 0.610 |
Why?
|
| Chromosomes, Human, Pair 15 | 7 | 2010 | 66 | 0.610 |
Why?
|
| Adolescent | 74 | 2021 | 9895 | 0.610 |
Why?
|
| Genetic Markers | 33 | 2021 | 479 | 0.610 |
Why?
|
| Receptors, Kainic Acid | 1 | 2019 | 13 | 0.600 |
Why?
|
| Hirschsprung Disease | 1 | 2019 | 13 | 0.600 |
Why?
|
| Leukopenia | 3 | 2025 | 68 | 0.600 |
Why?
|
| Cystic Fibrosis | 1 | 2020 | 121 | 0.590 |
Why?
|
| Pyrophosphatases | 3 | 2025 | 17 | 0.590 |
Why?
|
| Alternative Splicing | 5 | 2016 | 220 | 0.590 |
Why?
|
| Models, Biological | 9 | 2021 | 1809 | 0.590 |
Why?
|
| Laboratories | 1 | 2019 | 48 | 0.590 |
Why?
|
| Vaccines, Attenuated | 15 | 2015 | 57 | 0.590 |
Why?
|
| Vaccination | 17 | 2017 | 311 | 0.590 |
Why?
|
| Probability | 5 | 2021 | 365 | 0.590 |
Why?
|
| Hearing Loss | 4 | 2022 | 65 | 0.580 |
Why?
|
| Music | 3 | 2024 | 35 | 0.570 |
Why?
|
| Tamoxifen | 3 | 2014 | 171 | 0.570 |
Why?
|
| Antigenic Variation | 9 | 2016 | 28 | 0.570 |
Why?
|
| Seasons | 14 | 2016 | 246 | 0.570 |
Why?
|
| Genetic Diseases, Inborn | 7 | 2021 | 100 | 0.560 |
Why?
|
| Clinical Trials as Topic | 5 | 2021 | 1179 | 0.560 |
Why?
|
| Human Genetics | 1 | 2018 | 8 | 0.550 |
Why?
|
| Vascular Diseases | 1 | 2019 | 123 | 0.550 |
Why?
|
| Viral Proteins | 10 | 2016 | 289 | 0.550 |
Why?
|
| Hemagglutinins, Viral | 12 | 2000 | 38 | 0.550 |
Why?
|
| Women | 1 | 2018 | 26 | 0.550 |
Why?
|
| Embryo, Nonmammalian | 1 | 2019 | 203 | 0.550 |
Why?
|
| Leukocytes | 5 | 2023 | 218 | 0.540 |
Why?
|
| Influenza A Virus, H2N2 Subtype | 6 | 2014 | 10 | 0.540 |
Why?
|
| Founder Effect | 7 | 2001 | 106 | 0.540 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2014 | 644 | 0.540 |
Why?
|
| Polymorphism, Restriction Fragment Length | 21 | 2005 | 147 | 0.530 |
Why?
|
| Knowledge | 1 | 2017 | 29 | 0.530 |
Why?
|
| Cell Line | 32 | 2016 | 2537 | 0.530 |
Why?
|
| Cardiovascular Diseases | 5 | 2021 | 777 | 0.530 |
Why?
|
| Organizational Innovation | 1 | 2017 | 47 | 0.530 |
Why?
|
| Obsessive-Compulsive Disorder | 8 | 2014 | 160 | 0.520 |
Why?
|
| Cultural Diversity | 1 | 2018 | 68 | 0.520 |
Why?
|
| Cognitive Dysfunction | 4 | 2022 | 192 | 0.520 |
Why?
|
| Psychiatry | 2 | 2008 | 90 | 0.520 |
Why?
|
| Infant | 41 | 2021 | 3363 | 0.510 |
Why?
|
| Obesity | 14 | 2023 | 1030 | 0.510 |
Why?
|
| Base Sequence | 38 | 2011 | 2344 | 0.500 |
Why?
|
| Brain | 10 | 2024 | 2482 | 0.490 |
Why?
|
| Mutation | 31 | 2024 | 4374 | 0.490 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 2 | 2014 | 5 | 0.490 |
Why?
|
| Databases, Factual | 4 | 2025 | 1010 | 0.490 |
Why?
|
| Peripheral Nervous System Diseases | 4 | 2022 | 91 | 0.480 |
Why?
|
| Aged | 69 | 2025 | 20968 | 0.480 |
Why?
|
| Chromosomes, Human, Pair 3 | 3 | 2016 | 54 | 0.480 |
Why?
|
| Biomarkers | 6 | 2021 | 1930 | 0.470 |
Why?
|
| MicroRNAs | 8 | 2018 | 591 | 0.470 |
Why?
|
| Blood Glucose | 11 | 2017 | 873 | 0.460 |
Why?
|
| Mixed Function Oxygenases | 3 | 2014 | 69 | 0.460 |
Why?
|
| United Kingdom | 8 | 2021 | 192 | 0.460 |
Why?
|
| Zoonoses | 2 | 2014 | 28 | 0.450 |
Why?
|
| Drug Resistance, Viral | 9 | 2014 | 48 | 0.440 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2021 | 540 | 0.440 |
Why?
|
| Warfarin | 3 | 2013 | 107 | 0.440 |
Why?
|
| Neoplasms | 10 | 2022 | 3248 | 0.440 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 44 | 0.440 |
Why?
|
| Whole Genome Sequencing | 6 | 2025 | 109 | 0.430 |
Why?
|
| Polycystic Ovary Syndrome | 7 | 2009 | 208 | 0.430 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 1346 | 0.430 |
Why?
|
| Drug Discovery | 2 | 2012 | 118 | 0.430 |
Why?
|
| Chromosomes, Human, Pair 13 | 3 | 2015 | 51 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 16 | 5 | 2021 | 79 | 0.420 |
Why?
|
| Gene Regulatory Networks | 6 | 2020 | 322 | 0.420 |
Why?
|
| Exons | 6 | 2012 | 454 | 0.420 |
Why?
|
| Diabetes Complications | 4 | 2012 | 175 | 0.420 |
Why?
|
| Ferrets | 18 | 2016 | 50 | 0.410 |
Why?
|
| Ice Cover | 1 | 2013 | 2 | 0.410 |
Why?
|
| Cohort Studies | 24 | 2025 | 3110 | 0.410 |
Why?
|
| Epistasis, Genetic | 4 | 2010 | 92 | 0.410 |
Why?
|
| Biomarkers, Tumor | 6 | 2021 | 1670 | 0.410 |
Why?
|
| Glucuronosyltransferase | 4 | 2021 | 186 | 0.410 |
Why?
|
| Apolipoprotein L1 | 2 | 2023 | 7 | 0.410 |
Why?
|
| Systems Biology | 2 | 2014 | 47 | 0.410 |
Why?
|
| Estrogen Antagonists | 1 | 2013 | 48 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 2 | 11 | 2010 | 85 | 0.400 |
Why?
|
| Testicular Neoplasms | 3 | 2022 | 123 | 0.400 |
Why?
|
| Genome, Viral | 9 | 2012 | 80 | 0.400 |
Why?
|
| Information Dissemination | 3 | 2017 | 126 | 0.390 |
Why?
|
| Polymerase Chain Reaction | 13 | 2011 | 930 | 0.390 |
Why?
|
| Schizophrenia | 6 | 2021 | 532 | 0.390 |
Why?
|
| Attitude of Health Personnel | 2 | 2008 | 682 | 0.390 |
Why?
|
| Exome | 7 | 2019 | 141 | 0.390 |
Why?
|
| History, 20th Century | 5 | 2018 | 327 | 0.390 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2012 | 423 | 0.390 |
Why?
|
| Amino Acid Sequence | 28 | 2013 | 2090 | 0.390 |
Why?
|
| Climate Change | 1 | 2013 | 62 | 0.380 |
Why?
|
| RNA, Viral | 19 | 2009 | 311 | 0.380 |
Why?
|
| Sequence Analysis, DNA | 14 | 2021 | 910 | 0.380 |
Why?
|
| Chromosome Deletion | 2 | 2025 | 229 | 0.380 |
Why?
|
| Transcription Factors | 13 | 2018 | 1730 | 0.380 |
Why?
|
| Body Mass Index | 11 | 2025 | 815 | 0.380 |
Why?
|
| Molecular Epidemiology | 4 | 2011 | 58 | 0.380 |
Why?
|
| Organ Specificity | 7 | 2021 | 286 | 0.380 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 469 | 0.380 |
Why?
|
| Triglycerides | 3 | 2024 | 235 | 0.370 |
Why?
|
| Endophenotypes | 3 | 2025 | 19 | 0.370 |
Why?
|
| Reproducibility of Results | 14 | 2020 | 2880 | 0.370 |
Why?
|
| Privacy | 1 | 2012 | 20 | 0.370 |
Why?
|
| Sex Factors | 11 | 2020 | 1133 | 0.370 |
Why?
|
| Genetics, Population | 8 | 2017 | 437 | 0.370 |
Why?
|
| Endoplasmic Reticulum | 1 | 2014 | 264 | 0.370 |
Why?
|
| Vaccines, Inactivated | 11 | 2015 | 36 | 0.370 |
Why?
|
| Disease Susceptibility | 12 | 2021 | 220 | 0.360 |
Why?
|
| Hypersensitivity, Immediate | 3 | 2004 | 65 | 0.360 |
Why?
|
| Phylogeny | 26 | 2015 | 1275 | 0.360 |
Why?
|
| Anticoagulants | 3 | 2013 | 463 | 0.360 |
Why?
|
| Amantadine | 6 | 2007 | 19 | 0.360 |
Why?
|
| History, 21st Century | 3 | 2018 | 192 | 0.350 |
Why?
|
| Cell Line, Tumor | 14 | 2019 | 2778 | 0.350 |
Why?
|
| Hypertension | 4 | 2023 | 774 | 0.350 |
Why?
|
| RNA-Binding Proteins | 6 | 2017 | 305 | 0.350 |
Why?
|
| Tobacco Use Disorder | 2 | 2024 | 122 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 6 | 8 | 2013 | 128 | 0.350 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2011 | 21 | 0.350 |
Why?
|
| Cell Membrane | 2 | 2014 | 695 | 0.350 |
Why?
|
| Abnormalities, Multiple | 2 | 2025 | 238 | 0.340 |
Why?
|
| Inflammation | 4 | 2025 | 1063 | 0.340 |
Why?
|
| Research Design | 10 | 2021 | 631 | 0.340 |
Why?
|
| Liver | 9 | 2016 | 1238 | 0.330 |
Why?
|
| Metabolic Syndrome | 5 | 2020 | 123 | 0.330 |
Why?
|
| Tinnitus | 2 | 2022 | 24 | 0.330 |
Why?
|
| Hypertriglyceridemia | 2 | 2024 | 72 | 0.320 |
Why?
|
| Bipolar Disorder | 8 | 2014 | 405 | 0.320 |
Why?
|
| China | 7 | 2019 | 264 | 0.320 |
Why?
|
| Risk Assessment | 6 | 2020 | 2480 | 0.320 |
Why?
|
| Biological Evolution | 8 | 2024 | 1030 | 0.320 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2020 | 244 | 0.310 |
Why?
|
| Insulin Resistance | 6 | 2017 | 380 | 0.310 |
Why?
|
| Immunosuppressive Agents | 3 | 2025 | 995 | 0.310 |
Why?
|
| Health Literacy | 1 | 2010 | 77 | 0.310 |
Why?
|
| Texas | 9 | 2025 | 131 | 0.310 |
Why?
|
| Depressive Disorder, Major | 2 | 2022 | 174 | 0.310 |
Why?
|
| Models, Statistical | 5 | 2012 | 594 | 0.300 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2021 | 306 | 0.300 |
Why?
|
| Virulence | 12 | 2014 | 279 | 0.300 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2022 | 188 | 0.300 |
Why?
|
| Respiratory Mucosa | 4 | 2014 | 90 | 0.300 |
Why?
|
| DNA-Binding Proteins | 8 | 2023 | 1267 | 0.300 |
Why?
|
| Cognitive Reserve | 2 | 2020 | 5 | 0.300 |
Why?
|
| Mendelian Randomization Analysis | 4 | 2023 | 50 | 0.300 |
Why?
|
| DNA | 13 | 2019 | 1333 | 0.300 |
Why?
|
| Comorbidity | 5 | 2025 | 1011 | 0.300 |
Why?
|
| Young Adult | 22 | 2019 | 7025 | 0.290 |
Why?
|
| Carboplatin | 6 | 2011 | 331 | 0.290 |
Why?
|
| Mice, Inbred BALB C | 17 | 2014 | 1124 | 0.290 |
Why?
|
| Sepsis | 2 | 2023 | 391 | 0.290 |
Why?
|
| Environmental Exposure | 2 | 2011 | 357 | 0.290 |
Why?
|
| Receptors, Virus | 5 | 2011 | 77 | 0.290 |
Why?
|
| Aged, 80 and over | 24 | 2021 | 7229 | 0.290 |
Why?
|
| Pharmaceutical Preparations | 3 | 2022 | 97 | 0.290 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2022 | 29 | 0.290 |
Why?
|
| Sample Size | 4 | 2018 | 128 | 0.290 |
Why?
|
| Patient Education as Topic | 2 | 2010 | 378 | 0.280 |
Why?
|
| Cluster Analysis | 7 | 2023 | 393 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 11 | 7 | 2006 | 107 | 0.280 |
Why?
|
| Family | 7 | 2005 | 332 | 0.270 |
Why?
|
| Chromosomes, Human | 4 | 2008 | 67 | 0.270 |
Why?
|
| Protein Isoforms | 1 | 2008 | 296 | 0.270 |
Why?
|
| Genes | 4 | 2014 | 308 | 0.270 |
Why?
|
| Aging | 5 | 2020 | 766 | 0.270 |
Why?
|
| Mice | 31 | 2021 | 12537 | 0.260 |
Why?
|
| Hemagglutination Inhibition Tests | 14 | 2009 | 42 | 0.260 |
Why?
|
| Chickens | 9 | 2015 | 213 | 0.260 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 169 | 0.260 |
Why?
|
| Swine | 10 | 2013 | 598 | 0.260 |
Why?
|
| Likelihood Functions | 8 | 2006 | 257 | 0.260 |
Why?
|
| Biopsy | 3 | 2021 | 1220 | 0.260 |
Why?
|
| Rare Diseases | 3 | 2021 | 71 | 0.250 |
Why?
|
| Receptor, Insulin | 5 | 2002 | 60 | 0.250 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2018 | 307 | 0.250 |
Why?
|
| Diabetes Mellitus | 4 | 2007 | 771 | 0.250 |
Why?
|
| Mutation, Missense | 10 | 2023 | 302 | 0.240 |
Why?
|
| Mexico | 7 | 2016 | 74 | 0.240 |
Why?
|
| Aorta | 2 | 2018 | 294 | 0.240 |
Why?
|
| Cross Protection | 3 | 2017 | 11 | 0.240 |
Why?
|
| Rimantadine | 5 | 2007 | 9 | 0.240 |
Why?
|
| Signal Transduction | 9 | 2021 | 3581 | 0.240 |
Why?
|
| Linear Models | 7 | 2017 | 438 | 0.230 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2025 | 4 | 0.230 |
Why?
|
| Age Factors | 15 | 2020 | 1963 | 0.230 |
Why?
|
| Hemagglutinins | 3 | 2015 | 22 | 0.230 |
Why?
|
| Dyslexia | 2 | 2024 | 12 | 0.230 |
Why?
|
| American Heart Association | 2 | 2023 | 110 | 0.230 |
Why?
|
| Host-Pathogen Interactions | 5 | 2020 | 241 | 0.230 |
Why?
|
| Amino Acid Substitution | 11 | 2016 | 336 | 0.230 |
Why?
|
| Oligonucleotides | 4 | 1989 | 92 | 0.230 |
Why?
|
| Endocytosis | 2 | 2021 | 186 | 0.220 |
Why?
|
| Viral Core Proteins | 4 | 2014 | 28 | 0.220 |
Why?
|
| Chromosomes, Human, Y | 1 | 2025 | 26 | 0.220 |
Why?
|
| Antibodies, Antinuclear | 1 | 2025 | 95 | 0.220 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2020 | 187 | 0.220 |
Why?
|
| Congenital Abnormalities | 1 | 2025 | 68 | 0.220 |
Why?
|
| Adipose Tissue | 4 | 2016 | 269 | 0.220 |
Why?
|
| Glaucoma | 1 | 2025 | 36 | 0.220 |
Why?
|
| Hyperlipidemias | 2 | 2022 | 91 | 0.210 |
Why?
|
| Viral Matrix Proteins | 4 | 2011 | 14 | 0.210 |
Why?
|
| DNA, Neoplasm | 3 | 2014 | 272 | 0.210 |
Why?
|
| Knowledge Bases | 2 | 2021 | 15 | 0.210 |
Why?
|
| Germ-Line Mutation | 6 | 2020 | 382 | 0.210 |
Why?
|
| Disease Models, Animal | 15 | 2020 | 2534 | 0.210 |
Why?
|
| Temperature | 6 | 2014 | 426 | 0.210 |
Why?
|
| Neoplasm Proteins | 4 | 2017 | 553 | 0.210 |
Why?
|
| Chromosome Aberrations | 2 | 2024 | 393 | 0.210 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2024 | 19 | 0.210 |
Why?
|
| HSP40 Heat-Shock Proteins | 2 | 2016 | 18 | 0.210 |
Why?
|
| Day Care, Medical | 4 | 1999 | 11 | 0.210 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 555 | 0.210 |
Why?
|
| Intellectual Disability | 3 | 2021 | 203 | 0.210 |
Why?
|
| Cell Proliferation | 5 | 2024 | 1753 | 0.200 |
Why?
|
| HLA Antigens | 6 | 2004 | 231 | 0.200 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2023 | 13 | 0.200 |
Why?
|
| Sex Characteristics | 4 | 2022 | 339 | 0.200 |
Why?
|
| Disease Transmission, Infectious | 2 | 2002 | 60 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 569 | 0.200 |
Why?
|
| Carrier Proteins | 5 | 2017 | 683 | 0.200 |
Why?
|
| Acne Vulgaris | 1 | 2023 | 36 | 0.200 |
Why?
|
| Actinobacteria | 1 | 2023 | 11 | 0.200 |
Why?
|
| Exfoliation Syndrome | 1 | 2023 | 1 | 0.200 |
Why?
|
| Membrane Transport Proteins | 5 | 2017 | 170 | 0.200 |
Why?
|
| Influenza A Virus, H7N3 Subtype | 2 | 2013 | 3 | 0.200 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2020 | 57 | 0.200 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 1876 | 0.200 |
Why?
|
| Language | 1 | 2024 | 162 | 0.200 |
Why?
|
| Multimorbidity | 1 | 2023 | 6 | 0.200 |
Why?
|
| Cholesterol, LDL | 3 | 2023 | 246 | 0.200 |
Why?
|
| Promoter Regions, Genetic | 5 | 2020 | 996 | 0.200 |
Why?
|
| International Cooperation | 3 | 2019 | 134 | 0.200 |
Why?
|
| Computer Simulation | 12 | 2024 | 1158 | 0.200 |
Why?
|
| Islets of Langerhans | 8 | 2006 | 559 | 0.190 |
Why?
|
| Hong Kong | 15 | 2007 | 45 | 0.190 |
Why?
|
| Virus Attachment | 2 | 2014 | 6 | 0.190 |
Why?
|
| Multiple Sclerosis | 2 | 2022 | 263 | 0.190 |
Why?
|
| HLA-DR Antigens | 5 | 1991 | 59 | 0.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2014 | 154 | 0.190 |
Why?
|
| Otitis Media | 1 | 2022 | 20 | 0.190 |
Why?
|
| Kidney Diseases | 2 | 2023 | 323 | 0.190 |
Why?
|
| Adamantane | 3 | 2008 | 7 | 0.190 |
Why?
|
| Language Development Disorders | 2 | 2020 | 24 | 0.190 |
Why?
|
| Autoimmune Diseases | 2 | 2025 | 257 | 0.190 |
Why?
|
| Platinum | 2 | 2014 | 67 | 0.190 |
Why?
|
| Candidiasis | 1 | 2022 | 39 | 0.190 |
Why?
|
| Principal Component Analysis | 4 | 2020 | 168 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 1 | 4 | 2007 | 102 | 0.190 |
Why?
|
| Apolipoprotein A-V | 2 | 2024 | 2 | 0.190 |
Why?
|
| Risk | 10 | 2019 | 668 | 0.190 |
Why?
|
| Telomere | 1 | 2023 | 121 | 0.190 |
Why?
|
| Mercaptopurine | 1 | 2022 | 53 | 0.180 |
Why?
|
| Receptors, Cell Surface | 3 | 2021 | 298 | 0.180 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2020 | 38 | 0.180 |
Why?
|
| Herpes Zoster | 1 | 2022 | 80 | 0.180 |
Why?
|
| Odds Ratio | 7 | 2021 | 713 | 0.180 |
Why?
|
| Genome | 3 | 2021 | 407 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 12 | 3 | 2005 | 65 | 0.180 |
Why?
|
| Physicians | 2 | 2013 | 707 | 0.180 |
Why?
|
| Obesity, Morbid | 1 | 2025 | 247 | 0.180 |
Why?
|
| Fasting | 4 | 2017 | 164 | 0.180 |
Why?
|
| Leadership | 1 | 2024 | 159 | 0.180 |
Why?
|
| Speech Perception | 1 | 2022 | 74 | 0.180 |
Why?
|
| Overweight | 1 | 2023 | 121 | 0.180 |
Why?
|
| Homeodomain Proteins | 4 | 2018 | 563 | 0.180 |
Why?
|
| Hepatitis B | 1 | 2022 | 82 | 0.180 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2021 | 20 | 0.180 |
Why?
|
| Phosphoproteins | 4 | 2009 | 263 | 0.180 |
Why?
|
| Drug Repositioning | 1 | 2022 | 26 | 0.180 |
Why?
|
| DiGeorge Syndrome | 1 | 2021 | 11 | 0.180 |
Why?
|
| Health Equity | 1 | 2024 | 103 | 0.180 |
Why?
|
| Nuclear Proteins | 5 | 2017 | 750 | 0.180 |
Why?
|
| Poultry | 7 | 2013 | 24 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2023 | 403 | 0.180 |
Why?
|
| Bone Marrow Diseases | 1 | 2021 | 40 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2022 | 69 | 0.180 |
Why?
|
| Shock, Septic | 1 | 2023 | 125 | 0.180 |
Why?
|
| Viral Structural Proteins | 2 | 2007 | 17 | 0.180 |
Why?
|
| Duffy Blood-Group System | 1 | 2021 | 8 | 0.180 |
Why?
|
| Capecitabine | 2 | 2020 | 99 | 0.180 |
Why?
|
| Time Factors | 13 | 2018 | 5580 | 0.180 |
Why?
|
| Membrane Proteins | 4 | 2023 | 1276 | 0.180 |
Why?
|
| Pregnancy | 14 | 2024 | 3240 | 0.180 |
Why?
|
| Shear Strength | 1 | 2021 | 17 | 0.180 |
Why?
|
| Zebrafish | 3 | 2020 | 342 | 0.180 |
Why?
|
| Ducks | 3 | 2009 | 8 | 0.180 |
Why?
|
| Bone Marrow Examination | 1 | 2021 | 46 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 191 | 0.180 |
Why?
|
| Chromosome Disorders | 1 | 2021 | 112 | 0.180 |
Why?
|
| Hyperglycemia | 3 | 2012 | 181 | 0.180 |
Why?
|
| Environment | 5 | 2017 | 231 | 0.180 |
Why?
|
| Russia | 4 | 2013 | 28 | 0.180 |
Why?
|
| Anemia | 1 | 2022 | 137 | 0.170 |
Why?
|
| Introns | 5 | 2017 | 304 | 0.170 |
Why?
|
| Lymphocytes | 2 | 2018 | 489 | 0.170 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2021 | 60 | 0.170 |
Why?
|
| Virus Shedding | 4 | 2011 | 29 | 0.170 |
Why?
|
| Diabetic Retinopathy | 2 | 2012 | 82 | 0.170 |
Why?
|
| Japan | 11 | 2022 | 313 | 0.170 |
Why?
|
| Child Day Care Centers | 1 | 2000 | 6 | 0.170 |
Why?
|
| Periodicity | 1 | 2021 | 119 | 0.170 |
Why?
|
| Virulence Factors | 2 | 2014 | 113 | 0.170 |
Why?
|
| Neutropenia | 1 | 2021 | 218 | 0.170 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 7 | 1991 | 31 | 0.170 |
Why?
|
| Dermatitis, Atopic | 1 | 2021 | 66 | 0.170 |
Why?
|
| Recombination, Genetic | 10 | 2005 | 444 | 0.170 |
Why?
|
| Protein Transport | 5 | 2020 | 439 | 0.170 |
Why?
|
| Haploinsufficiency | 1 | 2021 | 69 | 0.170 |
Why?
|
| Biomedical Research | 2 | 2017 | 441 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 57 | 0.160 |
Why?
|
| Biological Transport | 1 | 2021 | 412 | 0.160 |
Why?
|
| Birds | 6 | 2014 | 173 | 0.160 |
Why?
|
| Europe | 9 | 2016 | 349 | 0.160 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2020 | 20 | 0.160 |
Why?
|
| Songbirds | 1 | 2021 | 85 | 0.160 |
Why?
|
| Genes, Regulator | 3 | 1989 | 65 | 0.160 |
Why?
|
| Loss of Heterozygosity | 2 | 2024 | 86 | 0.160 |
Why?
|
| Alcoholism | 2 | 2021 | 191 | 0.160 |
Why?
|
| Prognosis | 8 | 2021 | 4028 | 0.160 |
Why?
|
| Substance-Related Disorders | 1 | 2025 | 451 | 0.160 |
Why?
|
| Language Development | 2 | 2015 | 24 | 0.160 |
Why?
|
| Dementia | 4 | 2020 | 218 | 0.160 |
Why?
|
| Genetic Pleiotropy | 1 | 2020 | 29 | 0.160 |
Why?
|
| DEAD Box Protein 58 | 1 | 2020 | 11 | 0.160 |
Why?
|
| Genotyping Techniques | 3 | 2016 | 71 | 0.160 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2000 | 9 | 0.160 |
Why?
|
| Cigarette Smoking | 1 | 2021 | 48 | 0.160 |
Why?
|
| Prevalence | 6 | 2019 | 1349 | 0.160 |
Why?
|
| Autism Spectrum Disorder | 2 | 2021 | 87 | 0.160 |
Why?
|
| Vocalization, Animal | 1 | 2021 | 104 | 0.160 |
Why?
|
| Information Storage and Retrieval | 1 | 2020 | 127 | 0.160 |
Why?
|
| Chronic Pain | 1 | 2023 | 186 | 0.160 |
Why?
|
| Nuclear Family | 8 | 2002 | 94 | 0.160 |
Why?
|
| Hospitalization | 7 | 2014 | 943 | 0.160 |
Why?
|
| Societies, Medical | 1 | 2024 | 644 | 0.160 |
Why?
|
| Cardiology | 1 | 2021 | 130 | 0.160 |
Why?
|
| Selection, Genetic | 5 | 2021 | 537 | 0.160 |
Why?
|
| Cognitive Aging | 1 | 2019 | 9 | 0.160 |
Why?
|
| Membrane Glycoproteins | 4 | 2009 | 453 | 0.160 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 32 | 0.160 |
Why?
|
| Neuroblastoma | 2 | 2014 | 400 | 0.150 |
Why?
|
| Neanderthals | 1 | 2019 | 22 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 20 | 4 | 2004 | 32 | 0.150 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2020 | 76 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2015 | 841 | 0.150 |
Why?
|
| DNA Probes | 3 | 1990 | 77 | 0.150 |
Why?
|
| Retrospective Studies | 13 | 2023 | 10287 | 0.150 |
Why?
|
| Pregnancy Complications | 3 | 2012 | 356 | 0.150 |
Why?
|
| Tic Disorders | 1 | 2019 | 8 | 0.150 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2011 | 110 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 367 | 0.150 |
Why?
|
| Bayes Theorem | 6 | 2021 | 404 | 0.150 |
Why?
|
| HEK293 Cells | 4 | 2014 | 706 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 140 | 0.150 |
Why?
|
| Proteomics | 3 | 2023 | 268 | 0.150 |
Why?
|
| Post-Concussion Syndrome | 1 | 2019 | 21 | 0.150 |
Why?
|
| Coronary Disease | 2 | 2018 | 263 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 358 | 0.150 |
Why?
|
| Etoposide | 2 | 2011 | 212 | 0.150 |
Why?
|
| Infant, Newborn | 12 | 2019 | 2614 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 1 | 2023 | 432 | 0.150 |
Why?
|
| Lipoprotein(a) | 1 | 2018 | 30 | 0.150 |
Why?
|
| ATP-Binding Cassette Transporters | 6 | 2014 | 142 | 0.140 |
Why?
|
| Coronary Artery Disease | 2 | 2019 | 394 | 0.140 |
Why?
|
| Eggs | 2 | 2015 | 13 | 0.140 |
Why?
|
| Prefrontal Cortex | 1 | 2020 | 150 | 0.140 |
Why?
|
| Muscle Proteins | 2 | 2018 | 134 | 0.140 |
Why?
|
| DNA Primers | 11 | 2002 | 548 | 0.140 |
Why?
|
| Meta-Analysis as Topic | 5 | 2021 | 84 | 0.140 |
Why?
|
| Dogs | 9 | 2011 | 719 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2012 | 276 | 0.140 |
Why?
|
| Immunization | 2 | 2006 | 165 | 0.140 |
Why?
|
| Precision Medicine | 3 | 2023 | 454 | 0.140 |
Why?
|
| Serpins | 1 | 2018 | 31 | 0.140 |
Why?
|
| Statistical Distributions | 1 | 2018 | 9 | 0.140 |
Why?
|
| Zebrafish Proteins | 1 | 2020 | 160 | 0.140 |
Why?
|
| Hominidae | 1 | 2019 | 106 | 0.140 |
Why?
|
| Cognition Disorders | 2 | 2010 | 244 | 0.140 |
Why?
|
| Glucose | 5 | 2012 | 701 | 0.140 |
Why?
|
| Learning | 1 | 2021 | 305 | 0.140 |
Why?
|
| Rectum | 1 | 2019 | 151 | 0.140 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 125 | 0.140 |
Why?
|
| Aortic Rupture | 1 | 2018 | 58 | 0.140 |
Why?
|
| DNA Mutational Analysis | 5 | 2018 | 547 | 0.140 |
Why?
|
| Claudins | 1 | 2018 | 34 | 0.140 |
Why?
|
| Proteins | 4 | 2014 | 816 | 0.140 |
Why?
|
| Telomerase | 2 | 2024 | 68 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2010 | 115 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2021 | 287 | 0.140 |
Why?
|
| tau Proteins | 3 | 2019 | 98 | 0.140 |
Why?
|
| Technology, Pharmaceutical | 2 | 2015 | 36 | 0.140 |
Why?
|
| Epidemics | 1 | 2018 | 41 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 3 | 2016 | 259 | 0.140 |
Why?
|
| Hypertension, Pulmonary | 1 | 2022 | 381 | 0.140 |
Why?
|
| Chick Embryo | 8 | 2015 | 227 | 0.140 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 3 | 2003 | 8 | 0.140 |
Why?
|
| Glucose Tolerance Test | 8 | 2017 | 235 | 0.140 |
Why?
|
| Pemetrexed | 1 | 2018 | 76 | 0.140 |
Why?
|
| Health Resources | 1 | 2018 | 82 | 0.140 |
Why?
|
| Oseltamivir | 3 | 2014 | 20 | 0.140 |
Why?
|
| Inheritance Patterns | 5 | 2019 | 52 | 0.140 |
Why?
|
| Insurance Claim Reporting | 1 | 2017 | 3 | 0.140 |
Why?
|
| Contactins | 1 | 2017 | 2 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1316 | 0.130 |
Why?
|
| Repressor Proteins | 2 | 2020 | 447 | 0.130 |
Why?
|
| Models, Cardiovascular | 1 | 2018 | 110 | 0.130 |
Why?
|
| Skin Pigmentation | 1 | 2017 | 36 | 0.130 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2017 | 30 | 0.130 |
Why?
|
| Adaptation, Psychological | 2 | 2017 | 174 | 0.130 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2017 | 1 | 0.130 |
Why?
|
| Dyslipidemias | 1 | 2018 | 109 | 0.130 |
Why?
|
| Amyloidogenic Proteins | 1 | 2017 | 20 | 0.130 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2017 | 15 | 0.130 |
Why?
|
| Potassium Channels | 6 | 2007 | 359 | 0.130 |
Why?
|
| Adiposity | 2 | 2017 | 76 | 0.130 |
Why?
|
| Heat-Shock Proteins | 2 | 2008 | 184 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 64 | 0.130 |
Why?
|
| Apolipoproteins C | 1 | 1996 | 5 | 0.130 |
Why?
|
| RNA, Messenger | 7 | 2023 | 2090 | 0.130 |
Why?
|
| Polysaccharides | 3 | 2012 | 96 | 0.130 |
Why?
|
| Databases, Nucleic Acid | 2 | 2015 | 44 | 0.130 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2007 | 74 | 0.130 |
Why?
|
| Nucleoproteins | 4 | 2011 | 23 | 0.130 |
Why?
|
| Receptors, Drug | 5 | 2007 | 54 | 0.120 |
Why?
|
| RNA, Small Interfering | 5 | 2020 | 563 | 0.120 |
Why?
|
| Cognition | 3 | 2023 | 635 | 0.120 |
Why?
|
| Bronchi | 4 | 2012 | 234 | 0.120 |
Why?
|
| Lipid Metabolism | 2 | 2016 | 220 | 0.120 |
Why?
|
| Myocardium | 2 | 2016 | 592 | 0.120 |
Why?
|
| Age of Onset | 6 | 2017 | 344 | 0.120 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2011 | 64 | 0.120 |
Why?
|
| Serotonin | 2 | 2017 | 219 | 0.120 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 2 | 2014 | 11 | 0.120 |
Why?
|
| Christianity | 3 | 2001 | 37 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2020 | 464 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2016 | 22 | 0.120 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 346 | 0.120 |
Why?
|
| Transcription, Genetic | 3 | 2020 | 1192 | 0.120 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 3927 | 0.120 |
Why?
|
| Virus Cultivation | 5 | 2015 | 18 | 0.120 |
Why?
|
| Cross Reactions | 6 | 2012 | 115 | 0.120 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 4 | 2010 | 48 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 590 | 0.120 |
Why?
|
| Ribonucleoproteins | 1 | 2016 | 37 | 0.120 |
Why?
|
| Muscle, Skeletal | 3 | 2014 | 483 | 0.120 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2016 | 76 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 180 | 0.120 |
Why?
|
| RNA Splicing | 1 | 2017 | 159 | 0.120 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 1995 | 18 | 0.120 |
Why?
|
| Fibroblasts | 2 | 2020 | 777 | 0.120 |
Why?
|
| Neurons | 3 | 2021 | 1653 | 0.120 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 5 | 2007 | 124 | 0.120 |
Why?
|
| Heart Conduction System | 1 | 2016 | 126 | 0.120 |
Why?
|
| Bone Marrow Transplantation | 2 | 1998 | 294 | 0.120 |
Why?
|
| Geese | 2 | 2009 | 7 | 0.120 |
Why?
|
| DNA, Viral | 7 | 2002 | 274 | 0.120 |
Why?
|
| Heredity | 1 | 2015 | 20 | 0.120 |
Why?
|
| Birth Weight | 2 | 2013 | 152 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2021 | 301 | 0.110 |
Why?
|
| Melanoma | 2 | 2017 | 497 | 0.110 |
Why?
|
| Neutralization Tests | 8 | 2009 | 77 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1979 | 0.110 |
Why?
|
| Virion | 2 | 1995 | 62 | 0.110 |
Why?
|
| In Vitro Techniques | 3 | 2014 | 1010 | 0.110 |
Why?
|
| Mothers | 2 | 2010 | 155 | 0.110 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 65 | 0.110 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2016 | 106 | 0.110 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2015 | 9 | 0.110 |
Why?
|
| Respite Care | 2 | 1997 | 9 | 0.110 |
Why?
|
| Vaccines, Synthetic | 5 | 2014 | 60 | 0.110 |
Why?
|
| Homeostasis | 3 | 2014 | 467 | 0.110 |
Why?
|
| Germany | 5 | 2007 | 80 | 0.110 |
Why?
|
| Rural Population | 2 | 2011 | 171 | 0.110 |
Why?
|
| Civil Defense | 1 | 2014 | 11 | 0.110 |
Why?
|
| Vitamin K Epoxide Reductases | 2 | 2013 | 16 | 0.110 |
Why?
|
| Baculoviridae | 1 | 1995 | 34 | 0.110 |
Why?
|
| Cytochrome P-450 CYP2C9 | 2 | 2013 | 20 | 0.110 |
Why?
|
| Nedocromil | 1 | 2014 | 6 | 0.110 |
Why?
|
| Sampling Studies | 4 | 2008 | 76 | 0.110 |
Why?
|
| DNA Restriction Enzymes | 7 | 1991 | 97 | 0.110 |
Why?
|
| Regression Analysis | 3 | 2011 | 599 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 395 | 0.110 |
Why?
|
| Smoking | 3 | 2023 | 653 | 0.110 |
Why?
|
| Monosaccharide Transport Proteins | 3 | 1990 | 76 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 1 | 2015 | 174 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 412 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2006 | 83 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 81 | 0.110 |
Why?
|
| Hyperinsulinism | 2 | 2010 | 48 | 0.110 |
Why?
|
| Skin Neoplasms | 2 | 2017 | 625 | 0.110 |
Why?
|
| Poultry Diseases | 3 | 2009 | 13 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 725 | 0.110 |
Why?
|
| Nerve Growth Factors | 1 | 2014 | 61 | 0.110 |
Why?
|
| Actinin | 1 | 2014 | 19 | 0.110 |
Why?
|
| Oxo-Acid-Lyases | 1 | 2014 | 7 | 0.110 |
Why?
|
| Bias | 2 | 2005 | 139 | 0.110 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 137 | 0.110 |
Why?
|
| Cytosine | 1 | 2015 | 135 | 0.110 |
Why?
|
| Phosphofructokinase-1, Muscle Type | 1 | 2014 | 9 | 0.110 |
Why?
|
| Quality Control | 2 | 2014 | 125 | 0.110 |
Why?
|
| Consanguinity | 4 | 2005 | 73 | 0.100 |
Why?
|
| Survival Analysis | 5 | 2021 | 1546 | 0.100 |
Why?
|
| Family Health | 5 | 2017 | 159 | 0.100 |
Why?
|
| Genetics, Behavioral | 1 | 1993 | 22 | 0.100 |
Why?
|
| Euphoria | 1 | 2014 | 47 | 0.100 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 25 | 0.100 |
Why?
|
| Age Distribution | 6 | 2014 | 209 | 0.100 |
Why?
|
| Myocytes, Cardiac | 1 | 2016 | 323 | 0.100 |
Why?
|
| Antarctic Regions | 1 | 2013 | 10 | 0.100 |
Why?
|
| Pacific Ocean | 1 | 2013 | 19 | 0.100 |
Why?
|
| Genomic Imprinting | 2 | 2010 | 32 | 0.100 |
Why?
|
| Cholesterol | 3 | 2023 | 369 | 0.100 |
Why?
|
| Risk Reduction Behavior | 2 | 2011 | 99 | 0.100 |
Why?
|
| Therapeutics | 1 | 2013 | 13 | 0.100 |
Why?
|
| Femoral Neck Fractures | 1 | 2013 | 10 | 0.100 |
Why?
|
| Muscles | 2 | 2012 | 193 | 0.100 |
Why?
|
| Sleep | 1 | 2017 | 458 | 0.100 |
Why?
|
| Oligoribonucleotides | 2 | 1984 | 27 | 0.100 |
Why?
|
| Air | 1 | 2013 | 63 | 0.100 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2014 | 93 | 0.100 |
Why?
|
| Vitamin K | 1 | 2013 | 25 | 0.100 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 1 | 2013 | 3 | 0.100 |
Why?
|
| Viral Tropism | 1 | 2013 | 4 | 0.100 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 220 | 0.100 |
Why?
|
| Analysis of Variance | 2 | 2014 | 908 | 0.100 |
Why?
|
| Conjunctivitis | 1 | 2013 | 6 | 0.100 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2013 | 69 | 0.100 |
Why?
|
| Clusterin | 1 | 2013 | 14 | 0.100 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2013 | 68 | 0.100 |
Why?
|
| Seawater | 1 | 2013 | 50 | 0.100 |
Why?
|
| Cyclins | 1 | 2013 | 80 | 0.100 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2013 | 99 | 0.100 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1993 | 20 | 0.100 |
Why?
|
| Dextroamphetamine | 1 | 2014 | 108 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 2642 | 0.100 |
Why?
|
| Receptors, GABA-A | 2 | 2009 | 35 | 0.100 |
Why?
|
| Antifibrinolytic Agents | 1 | 2013 | 44 | 0.100 |
Why?
|
| Conserved Sequence | 3 | 2006 | 215 | 0.100 |
Why?
|
| Protein Interaction Maps | 1 | 2013 | 53 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2021 | 703 | 0.100 |
Why?
|
| Leukemia, Myeloid | 2 | 2009 | 252 | 0.100 |
Why?
|
| Treatment Failure | 3 | 2014 | 297 | 0.100 |
Why?
|
| Statistics as Topic | 3 | 2020 | 236 | 0.100 |
Why?
|
| Fibrillar Collagens | 1 | 2012 | 10 | 0.100 |
Why?
|
| Leukocyte Count | 2 | 2024 | 228 | 0.090 |
Why?
|
| Lipids | 2 | 2016 | 285 | 0.090 |
Why?
|
| Universities | 1 | 2013 | 154 | 0.090 |
Why?
|
| HLA-DQ Antigens | 2 | 1991 | 52 | 0.090 |
Why?
|
| Leucine | 2 | 2003 | 62 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 299 | 0.090 |
Why?
|
| Cytarabine | 1 | 2013 | 225 | 0.090 |
Why?
|
| Membrane Potentials | 1 | 2014 | 442 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2014 | 337 | 0.090 |
Why?
|
| Apoptosis | 3 | 2013 | 1756 | 0.090 |
Why?
|
| Cholesterol, HDL | 2 | 2023 | 173 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2012 | 2860 | 0.090 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2013 | 99 | 0.090 |
Why?
|
| Logistic Models | 4 | 2018 | 1268 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2014 | 386 | 0.090 |
Why?
|
| Cold Temperature | 6 | 2003 | 162 | 0.090 |
Why?
|
| Outpatients | 3 | 2020 | 105 | 0.090 |
Why?
|
| ErbB Receptors | 2 | 2021 | 513 | 0.090 |
Why?
|
| Postmenopause | 1 | 2012 | 107 | 0.090 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 1988 | 32 | 0.090 |
Why?
|
| Somatomedins | 2 | 1988 | 28 | 0.090 |
Why?
|
| Heart Failure | 1 | 2022 | 1422 | 0.090 |
Why?
|
| Nitriles | 1 | 2012 | 157 | 0.090 |
Why?
|
| Macular Edema | 1 | 2012 | 46 | 0.090 |
Why?
|
| Triazoles | 1 | 2012 | 110 | 0.090 |
Why?
|
| Public Health | 1 | 2013 | 155 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 187 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 684 | 0.090 |
Why?
|
| Treatment Outcome | 8 | 2018 | 9175 | 0.090 |
Why?
|
| Genealogy and Heraldry | 1 | 2011 | 13 | 0.090 |
Why?
|
| Glutathione Transferase | 2 | 2008 | 116 | 0.090 |
Why?
|
| Metabolomics | 1 | 2012 | 98 | 0.090 |
Why?
|
| Evolution, Molecular | 6 | 2016 | 891 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2013 | 294 | 0.090 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2011 | 28 | 0.090 |
Why?
|
| Mesothelioma | 2 | 2011 | 333 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 100 | 0.090 |
Why?
|
| Cloning, Molecular | 5 | 2011 | 648 | 0.090 |
Why?
|
| Rural Health Services | 1 | 2011 | 17 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 176 | 0.090 |
Why?
|
| Daunorubicin | 1 | 2011 | 78 | 0.090 |
Why?
|
| eIF-2 Kinase | 1 | 2011 | 50 | 0.090 |
Why?
|
| Mineral Fibers | 1 | 2011 | 2 | 0.090 |
Why?
|
| Protein Binding | 5 | 2016 | 1560 | 0.090 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2011 | 66 | 0.090 |
Why?
|
| Cost of Illness | 6 | 2010 | 161 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 1267 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 22 | 2 | 2008 | 41 | 0.080 |
Why?
|
| Rats | 4 | 2014 | 4155 | 0.080 |
Why?
|
| Chiroptera | 1 | 2012 | 56 | 0.080 |
Why?
|
| Virology | 1 | 2011 | 13 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2939 | 0.080 |
Why?
|
| Phosphorylation | 4 | 2020 | 1157 | 0.080 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2002 | 33 | 0.080 |
Why?
|
| Community Networks | 1 | 2011 | 32 | 0.080 |
Why?
|
| Adenosine Deaminase | 1 | 1991 | 27 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2014 | 477 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2012 | 216 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2012 | 497 | 0.080 |
Why?
|
| Population Groups | 1 | 2010 | 42 | 0.080 |
Why?
|
| Consumer Health Information | 1 | 2010 | 18 | 0.080 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2010 | 39 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 1215 | 0.080 |
Why?
|
| Chromosomes, Human, X | 1 | 2011 | 57 | 0.080 |
Why?
|
| Immunization Schedule | 2 | 2009 | 23 | 0.080 |
Why?
|
| TCF Transcription Factors | 1 | 2010 | 26 | 0.080 |
Why?
|
| Influenza A Virus, H5N2 Subtype | 2 | 2009 | 3 | 0.080 |
Why?
|
| GTP-Binding Proteins | 1 | 1991 | 148 | 0.080 |
Why?
|
| Gene-Environment Interaction | 1 | 2011 | 120 | 0.080 |
Why?
|
| Models, Molecular | 6 | 2014 | 1375 | 0.080 |
Why?
|
| Molecular Sequence Annotation | 2 | 2023 | 79 | 0.080 |
Why?
|
| Asparaginase | 1 | 2010 | 35 | 0.080 |
Why?
|
| Internet | 1 | 2013 | 340 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 311 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 1798 | 0.080 |
Why?
|
| Virus Diseases | 1 | 2011 | 102 | 0.080 |
Why?
|
| Hippocampus | 1 | 2014 | 459 | 0.080 |
Why?
|
| Environmental Pollutants | 1 | 2011 | 56 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1973 | 0.080 |
Why?
|
| Lung | 6 | 2014 | 1384 | 0.080 |
Why?
|
| Quality of Life | 4 | 2021 | 1816 | 0.080 |
Why?
|
| Genetic Techniques | 2 | 2005 | 75 | 0.080 |
Why?
|
| Drug Hypersensitivity | 1 | 2010 | 40 | 0.080 |
Why?
|
| Fluorouracil | 1 | 2012 | 555 | 0.080 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2010 | 49 | 0.080 |
Why?
|
| Pregnancy in Diabetics | 1 | 2010 | 41 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 117 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2010 | 137 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2012 | 481 | 0.080 |
Why?
|
| Receptors, AMPA | 1 | 2010 | 68 | 0.080 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 1805 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 2 | 2023 | 120 | 0.080 |
Why?
|
| Models, Theoretical | 3 | 2014 | 503 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2014 | 125 | 0.080 |
Why?
|
| Biostatistics | 1 | 2010 | 21 | 0.080 |
Why?
|
| Diabetic Nephropathies | 1 | 2010 | 90 | 0.080 |
Why?
|
| Drug Resistance, Microbial | 4 | 2001 | 72 | 0.080 |
Why?
|
| Antibody Formation | 3 | 2008 | 181 | 0.080 |
Why?
|
| Isoantigens | 1 | 2009 | 72 | 0.080 |
Why?
|
| Mathematics | 4 | 1997 | 191 | 0.080 |
Why?
|
| Genetic Heterogeneity | 2 | 2001 | 70 | 0.080 |
Why?
|
| Pleural Neoplasms | 1 | 2011 | 205 | 0.080 |
Why?
|
| Mice, Knockout | 4 | 2019 | 2161 | 0.080 |
Why?
|
| Natural Language Processing | 2 | 2020 | 42 | 0.080 |
Why?
|
| Health Promotion | 1 | 2011 | 176 | 0.080 |
Why?
|
| Monoamine Oxidase | 1 | 2009 | 25 | 0.070 |
Why?
|
| Social Behavior Disorders | 1 | 2009 | 20 | 0.070 |
Why?
|
| DNA Probes, HLA | 1 | 1988 | 2 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 1010 | 0.070 |
Why?
|
| Folic Acid | 1 | 2009 | 64 | 0.070 |
Why?
|
| Virus Internalization | 1 | 2009 | 45 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 810 | 0.070 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2008 | 42 | 0.070 |
Why?
|
| Gangliosides | 1 | 2008 | 10 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2012 | 442 | 0.070 |
Why?
|
| Genetic Phenomena | 1 | 2008 | 6 | 0.070 |
Why?
|
| Genetic Privacy | 1 | 2008 | 12 | 0.070 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2008 | 17 | 0.070 |
Why?
|
| Complex Mixtures | 1 | 2008 | 6 | 0.070 |
Why?
|
| Sequence Alignment | 4 | 2013 | 360 | 0.070 |
Why?
|
| Genes, Dominant | 3 | 2014 | 116 | 0.070 |
Why?
|
| Pancreas | 1 | 2010 | 264 | 0.070 |
Why?
|
| Codon | 3 | 1999 | 120 | 0.070 |
Why?
|
| Respiratory System | 4 | 2013 | 121 | 0.070 |
Why?
|
| Neutrophils | 1 | 2009 | 332 | 0.070 |
Why?
|
| Penetrance | 4 | 2013 | 48 | 0.070 |
Why?
|
| Microsatellite Repeats | 4 | 2002 | 151 | 0.070 |
Why?
|
| HMGB2 Protein | 1 | 2008 | 4 | 0.070 |
Why?
|
| Nerve Degeneration | 1 | 2008 | 84 | 0.070 |
Why?
|
| Speech | 2 | 2022 | 91 | 0.070 |
Why?
|
| High Mobility Group Proteins | 1 | 2008 | 27 | 0.070 |
Why?
|
| Population | 1 | 2008 | 37 | 0.070 |
Why?
|
| Confidentiality | 1 | 2008 | 79 | 0.070 |
Why?
|
| Binding Sites | 4 | 2020 | 1167 | 0.070 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 104 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 854 | 0.070 |
Why?
|
| Nucleocapsid Proteins | 4 | 2014 | 10 | 0.070 |
Why?
|
| Indonesia | 3 | 2007 | 12 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 258 | 0.070 |
Why?
|
| Medical Records | 1 | 2008 | 126 | 0.070 |
Why?
|
| Molecular Chaperones | 1 | 2008 | 127 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 1989 | 226 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 935 | 0.070 |
Why?
|
| Acclimatization | 3 | 2003 | 89 | 0.070 |
Why?
|
| Reference Standards | 3 | 2014 | 150 | 0.070 |
Why?
|
| Trans-Activators | 1 | 2010 | 446 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2007 | 47 | 0.070 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2009 | 176 | 0.070 |
Why?
|
| C-Peptide | 3 | 2013 | 186 | 0.070 |
Why?
|
| Protein Sorting Signals | 1 | 2007 | 42 | 0.070 |
Why?
|
| Ubiquitin | 1 | 2008 | 95 | 0.070 |
Why?
|
| Chromosome Segregation | 2 | 2004 | 35 | 0.070 |
Why?
|
| Coronary Stenosis | 1 | 2007 | 39 | 0.070 |
Why?
|
| Amyloid beta-Peptides | 2 | 2019 | 246 | 0.060 |
Why?
|
| Morbidity | 3 | 2004 | 160 | 0.060 |
Why?
|
| Tomography, Spiral Computed | 1 | 2007 | 77 | 0.060 |
Why?
|
| Homozygote | 2 | 2005 | 208 | 0.060 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2007 | 30 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2021 | 4671 | 0.060 |
Why?
|
| Thyroiditis, Autoimmune | 2 | 2020 | 17 | 0.060 |
Why?
|
| Respiratory Tract Diseases | 2 | 1999 | 47 | 0.060 |
Why?
|
| Genetic Vectors | 3 | 2011 | 446 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 247 | 0.060 |
Why?
|
| Oligonucleotide Probes | 1 | 2006 | 39 | 0.060 |
Why?
|
| Excitatory Amino Acid Transporter 3 | 1 | 2006 | 6 | 0.060 |
Why?
|
| Reference Values | 6 | 2009 | 674 | 0.060 |
Why?
|
| Transfection | 4 | 2011 | 908 | 0.060 |
Why?
|
| Programming Languages | 1 | 2006 | 16 | 0.060 |
Why?
|
| Indians, North American | 2 | 2011 | 48 | 0.060 |
Why?
|
| Monte Carlo Method | 4 | 1999 | 191 | 0.060 |
Why?
|
| Data Mining | 2 | 2020 | 44 | 0.060 |
Why?
|
| Lysine | 1 | 2008 | 190 | 0.060 |
Why?
|
| Abdominal Fat | 1 | 2006 | 13 | 0.060 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2003 | 53 | 0.060 |
Why?
|
| Chromosomes, Artificial, Yeast | 5 | 1996 | 36 | 0.060 |
Why?
|
| Species Specificity | 5 | 2005 | 707 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2007 | 261 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 4 | 2011 | 750 | 0.060 |
Why?
|
| Protein Conformation | 4 | 2014 | 935 | 0.060 |
Why?
|
| Horse Diseases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Influenza A Virus, H3N8 Subtype | 1 | 2005 | 1 | 0.060 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2005 | 11 | 0.060 |
Why?
|
| Upstream Stimulatory Factors | 1 | 2005 | 7 | 0.060 |
Why?
|
| Finland | 3 | 2017 | 31 | 0.060 |
Why?
|
| Microarray Analysis | 2 | 2021 | 98 | 0.060 |
Why?
|
| Ethics, Medical | 1 | 2008 | 312 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2008 | 162 | 0.060 |
Why?
|
| Dog Diseases | 1 | 2005 | 37 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 1471 | 0.060 |
Why?
|
| Informed Consent | 1 | 2008 | 281 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 311 | 0.060 |
Why?
|
| Siblings | 3 | 2014 | 109 | 0.060 |
Why?
|
| Survival Rate | 4 | 2013 | 1985 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 938 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 2463 | 0.060 |
Why?
|
| Reverse Genetics | 2 | 2015 | 3 | 0.060 |
Why?
|
| Antihypertensive Agents | 2 | 2022 | 264 | 0.060 |
Why?
|
| Viral Plaque Assay | 3 | 2011 | 19 | 0.060 |
Why?
|
| Sulfonylurea Receptors | 5 | 2007 | 50 | 0.060 |
Why?
|
| Heterozygote | 5 | 2007 | 382 | 0.060 |
Why?
|
| Mitochondria | 2 | 2013 | 622 | 0.060 |
Why?
|
| Serologic Tests | 2 | 2008 | 43 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 801 | 0.050 |
Why?
|
| North America | 4 | 2008 | 199 | 0.050 |
Why?
|
| Drug Interactions | 2 | 2021 | 245 | 0.050 |
Why?
|
| National Human Genome Research Institute (U.S.) | 1 | 2024 | 2 | 0.050 |
Why?
|
| Nigeria | 2 | 2007 | 162 | 0.050 |
Why?
|
| Vietnam | 3 | 2009 | 15 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2024 | 102 | 0.050 |
Why?
|
| Mites | 1 | 2004 | 17 | 0.050 |
Why?
|
| Eosinophils | 1 | 2025 | 199 | 0.050 |
Why?
|
| Bronchitis | 2 | 2020 | 7 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2016 | 80 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2014 | 153 | 0.050 |
Why?
|
| Janus Kinase 2 | 1 | 2024 | 59 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 5 | 2006 | 501 | 0.050 |
Why?
|
| Hyperlipidemia, Familial Combined | 1 | 2003 | 5 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 1089 | 0.050 |
Why?
|
| Iodide Peroxidase | 2 | 1999 | 215 | 0.050 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 417 | 0.050 |
Why?
|
| Biology | 1 | 2024 | 52 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2004 | 209 | 0.050 |
Why?
|
| Speech Disorders | 2 | 1993 | 19 | 0.050 |
Why?
|
| Cell Survival | 2 | 2019 | 1030 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 611 | 0.050 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 8 | 0.050 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2023 | 9 | 0.050 |
Why?
|
| Protein Interaction Mapping | 2 | 2014 | 81 | 0.050 |
Why?
|
| Rhabdoviridae | 1 | 1983 | 1 | 0.050 |
Why?
|
| Psychotic Disorders | 2 | 2021 | 231 | 0.050 |
Why?
|
| B7 Antigens | 1 | 2023 | 5 | 0.050 |
Why?
|
| Clostridiales | 1 | 2023 | 18 | 0.050 |
Why?
|
| Central Nervous System Sensitization | 1 | 2023 | 10 | 0.050 |
Why?
|
| Ebolavirus | 1 | 1983 | 6 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2023 | 55 | 0.050 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2003 | 26 | 0.050 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 31 | 0.050 |
Why?
|
| Biometry | 3 | 1997 | 72 | 0.050 |
Why?
|
| New York | 1 | 2023 | 75 | 0.050 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2003 | 23 | 0.050 |
Why?
|
| Sialic Acids | 3 | 2010 | 18 | 0.050 |
Why?
|
| Meat | 1 | 2003 | 27 | 0.050 |
Why?
|
| RNA, Small Nuclear | 1 | 2023 | 36 | 0.050 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2003 | 28 | 0.050 |
Why?
|
| Causality | 1 | 2023 | 84 | 0.050 |
Why?
|
| Thailand | 2 | 2013 | 66 | 0.050 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2023 | 34 | 0.050 |
Why?
|
| Warfare | 1 | 2002 | 12 | 0.050 |
Why?
|
| Sequence Analysis, Protein | 1 | 2002 | 28 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2006 | 304 | 0.050 |
Why?
|
| Kinetics | 2 | 2012 | 1562 | 0.050 |
Why?
|
| Eye Proteins | 1 | 2023 | 130 | 0.050 |
Why?
|
| Epoprostenol | 1 | 2022 | 46 | 0.050 |
Why?
|
| Individuality | 1 | 2023 | 114 | 0.050 |
Why?
|
| Sensation Disorders | 1 | 2022 | 31 | 0.050 |
Why?
|
| Scavenger Receptors, Class F | 1 | 2021 | 1 | 0.050 |
Why?
|
| Mutant Proteins | 2 | 2014 | 99 | 0.050 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2022 | 65 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2022 | 86 | 0.050 |
Why?
|
| Employment | 1 | 2002 | 57 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2024 | 327 | 0.040 |
Why?
|
| Resorcinols | 1 | 2021 | 5 | 0.040 |
Why?
|
| Recurrence | 3 | 2012 | 1218 | 0.040 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2021 | 25 | 0.040 |
Why?
|
| HapMap Project | 2 | 2012 | 47 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 1196 | 0.040 |
Why?
|
| Auditory Perception | 1 | 2023 | 105 | 0.040 |
Why?
|
| Perception | 1 | 2023 | 185 | 0.040 |
Why?
|
| Population Health | 1 | 2022 | 33 | 0.040 |
Why?
|
| Swine Diseases | 2 | 2013 | 15 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 66 | 0.040 |
Why?
|
| HN Protein | 1 | 2001 | 4 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 2002 | 57 | 0.040 |
Why?
|
| 3' Untranslated Regions | 2 | 2012 | 100 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2022 | 102 | 0.040 |
Why?
|
| Washington | 2 | 2006 | 51 | 0.040 |
Why?
|
| Tennessee | 1 | 2021 | 16 | 0.040 |
Why?
|
| Asia | 3 | 2008 | 105 | 0.040 |
Why?
|
| Asbestos | 2 | 2011 | 22 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2022 | 62 | 0.040 |
Why?
|
| Cell Nucleus | 2 | 2016 | 623 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 102 | 0.040 |
Why?
|
| Survivors | 1 | 2022 | 204 | 0.040 |
Why?
|
| Mice, Transgenic | 3 | 2016 | 1645 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2021 | 55 | 0.040 |
Why?
|
| False Positive Reactions | 2 | 2014 | 222 | 0.040 |
Why?
|
| Cross-Cultural Comparison | 1 | 2001 | 35 | 0.040 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2000 | 27 | 0.040 |
Why?
|
| Muscle Hypotonia | 1 | 2021 | 49 | 0.040 |
Why?
|
| South Dakota | 1 | 2000 | 47 | 0.040 |
Why?
|
| Dimaprit | 1 | 2020 | 1 | 0.040 |
Why?
|
| Ships | 1 | 2000 | 5 | 0.040 |
Why?
|
| Quail | 1 | 2000 | 8 | 0.040 |
Why?
|
| Bird Diseases | 1 | 2000 | 8 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2015 | 61 | 0.040 |
Why?
|
| Hypothyroidism | 2 | 2020 | 276 | 0.040 |
Why?
|
| Immunoglobulin E | 1 | 2001 | 152 | 0.040 |
Why?
|
| Finches | 1 | 2021 | 59 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2000 | 52 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2020 | 42 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2012 | 45 | 0.040 |
Why?
|
| Lipoproteins, LDL | 1 | 2020 | 84 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2002 | 688 | 0.040 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2023 | 422 | 0.040 |
Why?
|
| Coronaviridae Infections | 2 | 1990 | 6 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 28 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 156 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2020 | 14 | 0.040 |
Why?
|
| Cat Diseases | 2 | 1990 | 20 | 0.040 |
Why?
|
| Procollagen | 1 | 2020 | 8 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2020 | 196 | 0.040 |
Why?
|
| Tobacco Products | 1 | 2021 | 80 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2012 | 71 | 0.040 |
Why?
|
| Peritonitis | 2 | 1990 | 29 | 0.040 |
Why?
|
| Crystallography, X-Ray | 2 | 2014 | 527 | 0.040 |
Why?
|
| Travel | 1 | 2000 | 72 | 0.040 |
Why?
|
| A549 Cells | 1 | 2020 | 51 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2011 | 137 | 0.040 |
Why?
|
| Skin | 1 | 2023 | 605 | 0.040 |
Why?
|
| Artifacts | 1 | 2001 | 252 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 483 | 0.040 |
Why?
|
| Neuropilin-1 | 1 | 2019 | 14 | 0.040 |
Why?
|
| Musculoskeletal System | 1 | 2020 | 16 | 0.040 |
Why?
|
| Scleroderma, Systemic | 1 | 2020 | 59 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 57 | 0.040 |
Why?
|
| Reye Syndrome | 1 | 1999 | 22 | 0.040 |
Why?
|
| Secretory Pathway | 1 | 2020 | 23 | 0.040 |
Why?
|
| Chondrocytes | 1 | 2020 | 66 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 883 | 0.040 |
Why?
|
| Africa | 3 | 2007 | 107 | 0.040 |
Why?
|
| Loneliness | 1 | 2019 | 27 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 771 | 0.040 |
Why?
|
| Health Priorities | 1 | 1999 | 28 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 983 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 3489 | 0.040 |
Why?
|
| Pregnancy Outcome | 2 | 2012 | 273 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 1999 | 140 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2000 | 363 | 0.040 |
Why?
|
| Paraffin Embedding | 2 | 2014 | 79 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 145 | 0.040 |
Why?
|
| Incidence | 3 | 2017 | 1715 | 0.040 |
Why?
|
| Capital Financing | 1 | 1999 | 4 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2020 | 229 | 0.040 |
Why?
|
| RNA Interference | 1 | 2020 | 385 | 0.040 |
Why?
|
| Syndrome | 1 | 2020 | 453 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 1996 | 137 | 0.040 |
Why?
|
| DNA, Satellite | 2 | 1995 | 20 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2019 | 142 | 0.040 |
Why?
|
| Kidney | 3 | 2016 | 1137 | 0.040 |
Why?
|
| Gene Editing | 1 | 2019 | 52 | 0.040 |
Why?
|
| Parents | 3 | 2012 | 307 | 0.040 |
Why?
|
| Disease Management | 1 | 2021 | 360 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 526 | 0.040 |
Why?
|
| Restriction Mapping | 2 | 1996 | 152 | 0.040 |
Why?
|
| Genes, Reporter | 2 | 2012 | 281 | 0.040 |
Why?
|
| Health Services | 1 | 1999 | 58 | 0.040 |
Why?
|
| Military Personnel | 1 | 2020 | 104 | 0.040 |
Why?
|
| Pneumonia | 2 | 2014 | 197 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2018 | 95 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2020 | 351 | 0.040 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2019 | 132 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2011 | 79 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 255 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 897 | 0.030 |
Why?
|
| Sequestosome-1 Protein | 2 | 2008 | 23 | 0.030 |
Why?
|
| Body Weight | 2 | 2014 | 460 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2009 | 206 | 0.030 |
Why?
|
| Nursing Homes | 2 | 2000 | 113 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1998 | 60 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2020 | 277 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 1996 | 394 | 0.030 |
Why?
|
| HIV-1 | 1 | 1999 | 182 | 0.030 |
Why?
|
| Urethritis | 1 | 2017 | 2 | 0.030 |
Why?
|
| Inventions | 1 | 2017 | 14 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2018 | 136 | 0.030 |
Why?
|
| Cystitis | 1 | 2017 | 13 | 0.030 |
Why?
|
| Marriage | 1 | 1997 | 25 | 0.030 |
Why?
|
| Health Expenditures | 1 | 1999 | 101 | 0.030 |
Why?
|
| Poland | 1 | 1997 | 18 | 0.030 |
Why?
|
| Child Language | 1 | 1997 | 6 | 0.030 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2017 | 16 | 0.030 |
Why?
|
| Inpatients | 1 | 2020 | 347 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2010 | 458 | 0.030 |
Why?
|
| Nucleotide Motifs | 1 | 2017 | 49 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 186 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 328 | 0.030 |
Why?
|
| Contraindications | 2 | 2010 | 70 | 0.030 |
Why?
|
| Research Report | 1 | 2017 | 43 | 0.030 |
Why?
|
| Human Genome Project | 1 | 2017 | 22 | 0.030 |
Why?
|
| Asia, Southeastern | 2 | 2008 | 18 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2018 | 237 | 0.030 |
Why?
|
| Costs and Cost Analysis | 2 | 1997 | 157 | 0.030 |
Why?
|
| Markov Chains | 1 | 1997 | 137 | 0.030 |
Why?
|
| Migraine Disorders | 1 | 2017 | 43 | 0.030 |
Why?
|
| Financial Management | 1 | 1997 | 22 | 0.030 |
Why?
|
| Apolipoproteins A | 1 | 1996 | 10 | 0.030 |
Why?
|
| Apolipoprotein C-III | 1 | 1996 | 8 | 0.030 |
Why?
|
| Homeobox Protein Nkx-2.5 | 1 | 2016 | 13 | 0.030 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2017 | 46 | 0.030 |
Why?
|
| Matched-Pair Analysis | 3 | 2002 | 40 | 0.030 |
Why?
|
| Haploidy | 1 | 1996 | 32 | 0.030 |
Why?
|
| Military Medicine | 1 | 1997 | 24 | 0.030 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2016 | 27 | 0.030 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2016 | 32 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2020 | 394 | 0.030 |
Why?
|
| Italy | 1 | 1996 | 112 | 0.030 |
Why?
|
| Pulse Wave Analysis | 1 | 2016 | 10 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 873 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 1996 | 30 | 0.030 |
Why?
|
| Nucleotide Mapping | 3 | 1994 | 7 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1993 | 126 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 1996 | 63 | 0.030 |
Why?
|
| Amyloidosis | 1 | 2018 | 139 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 3 | 2002 | 57 | 0.030 |
Why?
|
| Patient Admission | 1 | 1997 | 122 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2018 | 477 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1994 | 422 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2007 | 2039 | 0.030 |
Why?
|
| tRNA Methyltransferases | 1 | 2016 | 14 | 0.030 |
Why?
|
| Glycogen Synthase | 1 | 1996 | 22 | 0.030 |
Why?
|
| Vascular Stiffness | 1 | 2016 | 30 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 11 | 0.030 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2016 | 17 | 0.030 |
Why?
|
| Pyrrolidinones | 1 | 2016 | 16 | 0.030 |
Why?
|
| Immune Evasion | 1 | 2016 | 37 | 0.030 |
Why?
|
| Denmark | 1 | 1995 | 19 | 0.030 |
Why?
|
| Macular Degeneration | 1 | 1996 | 51 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2011 | 376 | 0.030 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2016 | 48 | 0.030 |
Why?
|
| Organizational Case Studies | 2 | 2011 | 28 | 0.030 |
Why?
|
| Models, Animal | 1 | 2017 | 286 | 0.030 |
Why?
|
| Serial Passage | 1 | 2015 | 3 | 0.030 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 45 | 0.030 |
Why?
|
| Cancer Survivors | 1 | 2017 | 88 | 0.030 |
Why?
|
| Thimerosal | 2 | 2006 | 6 | 0.030 |
Why?
|
| Preservatives, Pharmaceutical | 2 | 2006 | 9 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 91 | 0.030 |
Why?
|
| Community Health Centers | 1 | 1997 | 120 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 157 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 901 | 0.030 |
Why?
|
| Amyloid | 1 | 1996 | 105 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 107 | 0.030 |
Why?
|
| Allantois | 1 | 1995 | 3 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1995 | 54 | 0.030 |
Why?
|
| Gastrostomy | 1 | 1995 | 69 | 0.030 |
Why?
|
| Receptors, Glucagon | 1 | 2015 | 11 | 0.030 |
Why?
|
| Phylogeography | 1 | 2015 | 50 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2015 | 10 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 1995 | 105 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 256 | 0.030 |
Why?
|
| Ovum | 1 | 2015 | 61 | 0.030 |
Why?
|
| Hyperthyroxinemia | 1 | 1995 | 17 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2015 | 82 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 40 | 0.030 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 31 | 0.030 |
Why?
|
| Web Browser | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cambodia | 1 | 2014 | 6 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 53 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 2014 | 67 | 0.030 |
Why?
|
| Heart Atria | 1 | 2016 | 290 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 1995 | 128 | 0.030 |
Why?
|
| Netrins | 1 | 2014 | 6 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 1995 | 146 | 0.030 |
Why?
|
| Sequence Homology | 1 | 1994 | 28 | 0.030 |
Why?
|
| Peroxisome-Targeting Signal 1 Receptor | 1 | 2014 | 3 | 0.030 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 71 | 0.030 |
Why?
|
| Indazoles | 1 | 2014 | 61 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 2014 | 49 | 0.030 |
Why?
|
| Serum Albumin | 1 | 1995 | 128 | 0.030 |
Why?
|
| Budesonide | 1 | 2014 | 46 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2014 | 82 | 0.030 |
Why?
|
| Cyclohexylamines | 1 | 2014 | 8 | 0.030 |
Why?
|
| Basal Metabolism | 1 | 2014 | 19 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 83 | 0.030 |
Why?
|
| Chromatography, Gel | 1 | 2014 | 104 | 0.030 |
Why?
|
| Animal Structures | 1 | 2014 | 27 | 0.030 |
Why?
|
| Protective Agents | 1 | 2014 | 34 | 0.030 |
Why?
|
| Gene Deletion | 2 | 2008 | 358 | 0.030 |
Why?
|
| Deglutition Disorders | 1 | 1995 | 126 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2015 | 167 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2009 | 175 | 0.030 |
Why?
|
| Thinness | 1 | 2014 | 45 | 0.030 |
Why?
|
| Twins, Monozygotic | 1 | 2014 | 58 | 0.030 |
Why?
|
| Poisson Distribution | 2 | 2004 | 49 | 0.030 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2014 | 49 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 106 | 0.030 |
Why?
|
| Health Records, Personal | 1 | 2013 | 11 | 0.030 |
Why?
|
| Hypothalamus | 1 | 2014 | 80 | 0.030 |
Why?
|
| Simvastatin | 1 | 2014 | 106 | 0.030 |
Why?
|
| Speech Production Measurement | 1 | 1993 | 9 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 2014 | 91 | 0.030 |
Why?
|
| Diagnosis | 1 | 2013 | 18 | 0.030 |
Why?
|
| Cell Count | 1 | 2014 | 203 | 0.030 |
Why?
|
| Pharmacokinetics | 1 | 2013 | 11 | 0.030 |
Why?
|
| Contact Tracing | 1 | 2013 | 29 | 0.030 |
Why?
|
| Serine Peptidase Inhibitor Kazal-Type 5 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Health Plan Implementation | 1 | 1994 | 65 | 0.030 |
Why?
|
| Forecasting | 2 | 2008 | 317 | 0.020 |
Why?
|
| Caribbean Region | 1 | 2013 | 27 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2008 | 396 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 138 | 0.020 |
Why?
|
| Placebos | 1 | 1993 | 213 | 0.020 |
Why?
|
| Bacterial Proteins | 2 | 1991 | 922 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 313 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2013 | 56 | 0.020 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 1993 | 8 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2014 | 224 | 0.020 |
Why?
|
| Multilocus Sequence Typing | 1 | 2013 | 13 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 303 | 0.020 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2012 | 11 | 0.020 |
Why?
|
| Viral Envelope Proteins | 1 | 1993 | 95 | 0.020 |
Why?
|
| Publishing | 1 | 2014 | 94 | 0.020 |
Why?
|
| Respiratory Therapy | 1 | 1993 | 17 | 0.020 |
Why?
|
| RNA Isoforms | 1 | 2012 | 5 | 0.020 |
Why?
|
| Skin Tests | 2 | 2004 | 47 | 0.020 |
Why?
|
| Glycogen Phosphorylase | 1 | 2012 | 6 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 509 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 299 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2013 | 162 | 0.020 |
Why?
|
| Chicago | 2 | 2013 | 1506 | 0.020 |
Why?
|
| SAP90-PSD95 Associated Proteins | 1 | 2012 | 2 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 504 | 0.020 |
Why?
|
| Biotransformation | 1 | 2012 | 49 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 1034 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2013 | 123 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 220 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2014 | 280 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2012 | 44 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2017 | 824 | 0.020 |
Why?
|
| Data Collection | 2 | 1997 | 381 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2014 | 196 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2014 | 433 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2013 | 128 | 0.020 |
Why?
|
| NADP | 2 | 2003 | 49 | 0.020 |
Why?
|
| Receptors, Adiponectin | 1 | 2012 | 4 | 0.020 |
Why?
|
| Resistin | 1 | 2012 | 12 | 0.020 |
Why?
|
| Guatemala | 1 | 2012 | 6 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2012 | 33 | 0.020 |
Why?
|
| Rabbits | 1 | 1993 | 639 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 1993 | 94 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2012 | 55 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2012 | 88 | 0.020 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 1992 | 10 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2012 | 70 | 0.020 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2004 | 77 | 0.020 |
Why?
|
| Students | 1 | 2013 | 179 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 325 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2012 | 131 | 0.020 |
Why?
|
| Uveal Neoplasms | 1 | 2011 | 11 | 0.020 |
Why?
|
| Southwestern United States | 1 | 2011 | 7 | 0.020 |
Why?
|
| Virus Physiological Phenomena | 1 | 2011 | 8 | 0.020 |
Why?
|
| Deoxycytidine Kinase | 1 | 2011 | 4 | 0.020 |
Why?
|
| Virginia | 1 | 2011 | 16 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2016 | 810 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2011 | 54 | 0.020 |
Why?
|
| Cytogenetics | 1 | 2011 | 28 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2011 | 53 | 0.020 |
Why?
|
| Epidemiologic Methods | 2 | 1989 | 60 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 195 | 0.020 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2012 | 106 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1991 | 49 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 64 | 0.020 |
Why?
|
| Geography | 1 | 2012 | 240 | 0.020 |
Why?
|
| Radiation Effects | 1 | 2011 | 28 | 0.020 |
Why?
|
| Zeolites | 1 | 2011 | 4 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 2011 | 11 | 0.020 |
Why?
|
| Carcinogens, Environmental | 1 | 2011 | 7 | 0.020 |
Why?
|
| Health Status | 2 | 2005 | 386 | 0.020 |
Why?
|
| Diet | 1 | 2014 | 460 | 0.020 |
Why?
|
| Methylation | 1 | 2012 | 295 | 0.020 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 39 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1176 | 0.020 |
Why?
|
| Micronucleus, Germline | 1 | 2010 | 3 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2012 | 281 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2011 | 82 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 367 | 0.020 |
Why?
|
| Immunization Programs | 1 | 2010 | 26 | 0.020 |
Why?
|
| Interpersonal Relations | 2 | 2004 | 182 | 0.020 |
Why?
|
| Viruses | 1 | 2011 | 75 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 769 | 0.020 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2010 | 32 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 1990 | 45 | 0.020 |
Why?
|
| Disability Evaluation | 2 | 2002 | 171 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 291 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 264 | 0.020 |
Why?
|
| Cerebellum | 1 | 2012 | 253 | 0.020 |
Why?
|
| Antithrombin III | 1 | 1989 | 9 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 692 | 0.020 |
Why?
|
| Perilipin-1 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 354 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2011 | 165 | 0.020 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2010 | 56 | 0.020 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1989 | 32 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2010 | 329 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2010 | 86 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 58 | 0.020 |
Why?
|
| HIV Infections | 1 | 1999 | 974 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 147 | 0.020 |
Why?
|
| Arginine | 1 | 2009 | 144 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2010 | 133 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2001 | 182 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2010 | 118 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2009 | 159 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 558 | 0.020 |
Why?
|
| Minisatellite Repeats | 2 | 2002 | 24 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 1990 | 191 | 0.020 |
Why?
|
| Apolipoproteins | 1 | 1989 | 34 | 0.020 |
Why?
|
| Peptides | 2 | 2011 | 671 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 1988 | 36 | 0.020 |
Why?
|
| Topography, Medical | 1 | 2008 | 5 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2009 | 103 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 2 | 2000 | 30 | 0.020 |
Why?
|
| Peptide Library | 1 | 2009 | 85 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1990 | 436 | 0.020 |
Why?
|
| Carbohydrate Metabolism | 1 | 1988 | 32 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1991 | 432 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1988 | 242 | 0.020 |
Why?
|
| Gangliosidosis, GM1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Porcine Reproductive and Respiratory Syndrome | 1 | 2008 | 2 | 0.020 |
Why?
|
| Midazolam | 1 | 2008 | 49 | 0.020 |
Why?
|
| Color Perception | 1 | 1990 | 120 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2000 | 60 | 0.020 |
Why?
|
| Cause of Death | 2 | 2003 | 278 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 713 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 439 | 0.020 |
Why?
|
| Campylobacter jejuni | 1 | 2008 | 15 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2008 | 31 | 0.020 |
Why?
|
| Glycolipids | 1 | 2008 | 30 | 0.020 |
Why?
|
| Epoxide Hydrolases | 1 | 2008 | 7 | 0.020 |
Why?
|
| Oceania | 1 | 2008 | 5 | 0.020 |
Why?
|
| Neurofibrillary Tangles | 1 | 2008 | 48 | 0.020 |
Why?
|
| Isotopes | 1 | 2008 | 26 | 0.020 |
Why?
|
| Vaccinia virus | 1 | 1988 | 20 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 76 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 1989 | 183 | 0.020 |
Why?
|
| South America | 1 | 2008 | 36 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 816 | 0.020 |
Why?
|
| Deubiquitinating Enzyme CYLD | 1 | 2008 | 2 | 0.020 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2008 | 7 | 0.020 |
Why?
|
| Polyubiquitin | 1 | 2008 | 8 | 0.020 |
Why?
|
| Sulfurtransferases | 1 | 1988 | 6 | 0.020 |
Why?
|
| Receptor, trkA | 1 | 2008 | 14 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 813 | 0.020 |
Why?
|
| Wisconsin | 1 | 2008 | 46 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 113 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 372 | 0.020 |
Why?
|
| Adolescent Behavior | 1 | 2009 | 115 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 190 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2009 | 522 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 90 | 0.020 |
Why?
|
| Oxazines | 1 | 2007 | 15 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2008 | 112 | 0.020 |
Why?
|
| Calcium | 2 | 2003 | 1205 | 0.020 |
Why?
|
| Receptors, Cytokine | 1 | 2007 | 30 | 0.020 |
Why?
|
| Xanthenes | 1 | 2007 | 23 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2007 | 23 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2007 | 23 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2008 | 253 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2010 | 338 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2007 | 143 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2008 | 131 | 0.020 |
Why?
|
| Blood Platelets | 1 | 1988 | 156 | 0.020 |
Why?
|
| Antigens | 1 | 1988 | 231 | 0.020 |
Why?
|
| Kazakhstan | 1 | 2007 | 1 | 0.020 |
Why?
|
| International Agencies | 1 | 2007 | 34 | 0.020 |
Why?
|
| Glycoconjugates | 1 | 2007 | 11 | 0.020 |
Why?
|
| Galactose | 1 | 2007 | 34 | 0.020 |
Why?
|
| Proinsulin | 1 | 2007 | 124 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2007 | 138 | 0.020 |
Why?
|
| Adherens Junctions | 1 | 2007 | 35 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 2 | 1996 | 30 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 2 | 1996 | 34 | 0.020 |
Why?
|
| Oncogenes | 1 | 2007 | 100 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 1987 | 156 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 376 | 0.020 |
Why?
|
| Exercise | 1 | 2010 | 354 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2006 | 66 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 2 | 1996 | 80 | 0.020 |
Why?
|
| Nose | 1 | 2007 | 96 | 0.020 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2007 | 127 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 303 | 0.020 |
Why?
|
| Intestines | 1 | 2009 | 431 | 0.020 |
Why?
|
| Sequence Analysis | 1 | 2006 | 28 | 0.020 |
Why?
|
| Neuregulin-1 | 1 | 2006 | 17 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2005 | 6 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1986 | 270 | 0.010 |
Why?
|
| Horses | 1 | 2005 | 36 | 0.010 |
Why?
|
| Biological Assay | 1 | 2006 | 84 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 75 | 0.010 |
Why?
|
| Trypsin | 1 | 2005 | 95 | 0.010 |
Why?
|
| Patient Selection | 1 | 2009 | 709 | 0.010 |
Why?
|
| Florida | 1 | 2005 | 63 | 0.010 |
Why?
|
| Luciferases | 1 | 2005 | 130 | 0.010 |
Why?
|
| Genetic Engineering | 1 | 1986 | 120 | 0.010 |
Why?
|
| Protein Folding | 1 | 2007 | 295 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2008 | 340 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 2 | 2000 | 298 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2012 | 1667 | 0.010 |
Why?
|
| Color Vision Defects | 1 | 1985 | 22 | 0.010 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 1985 | 15 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2006 | 239 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 1172 | 0.010 |
Why?
|
| Dystonia Musculorum Deformans | 1 | 1984 | 1 | 0.010 |
Why?
|
| HLA-G Antigens | 1 | 2004 | 52 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 1996 | 366 | 0.010 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2004 | 22 | 0.010 |
Why?
|
| Cricetinae | 2 | 1995 | 542 | 0.010 |
Why?
|
| Gene Library | 2 | 1996 | 134 | 0.010 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2004 | 11 | 0.010 |
Why?
|
| Adenosine Triphosphate | 2 | 1996 | 329 | 0.010 |
Why?
|
| X Chromosome | 1 | 1985 | 157 | 0.010 |
Why?
|
| International Classification of Diseases | 1 | 2004 | 67 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2005 | 185 | 0.010 |
Why?
|
| Testosterone | 1 | 2005 | 277 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2004 | 28 | 0.010 |
Why?
|
| Primates | 1 | 2005 | 160 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2006 | 424 | 0.010 |
Why?
|
| Oropharynx | 1 | 2003 | 15 | 0.010 |
Why?
|
| Hyperlipoproteinemias | 1 | 2003 | 7 | 0.010 |
Why?
|
| Speech Therapy | 1 | 1983 | 9 | 0.010 |
Why?
|
| Hemorrhagic Fevers, Viral | 1 | 1983 | 3 | 0.010 |
Why?
|
| Mammals | 1 | 2005 | 261 | 0.010 |
Why?
|
| Fear | 1 | 2004 | 88 | 0.010 |
Why?
|
| Democratic Republic of the Congo | 1 | 1983 | 8 | 0.010 |
Why?
|
| Sudan | 1 | 1983 | 13 | 0.010 |
Why?
|
| Dipeptides | 1 | 2003 | 40 | 0.010 |
Why?
|
| Epitopes | 2 | 1999 | 258 | 0.010 |
Why?
|
| Lithium | 1 | 1983 | 63 | 0.010 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2002 | 8 | 0.010 |
Why?
|
| Control Groups | 1 | 2002 | 16 | 0.010 |
Why?
|
| Mood Disorders | 1 | 1983 | 83 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2003 | 133 | 0.010 |
Why?
|
| Cell Separation | 1 | 2003 | 205 | 0.010 |
Why?
|
| DNA, Recombinant | 2 | 1996 | 65 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2003 | 81 | 0.010 |
Why?
|
| Computer Graphics | 1 | 2003 | 102 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 510 | 0.010 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2002 | 56 | 0.010 |
Why?
|
| Zanamivir | 1 | 2002 | 2 | 0.010 |
Why?
|
| Pyrans | 1 | 2002 | 10 | 0.010 |
Why?
|
| Guanidines | 1 | 2002 | 33 | 0.010 |
Why?
|
| Acetamides | 1 | 2002 | 27 | 0.010 |
Why?
|
| England | 1 | 2002 | 39 | 0.010 |
Why?
|
| Ireland | 1 | 2002 | 12 | 0.010 |
Why?
|
| Haplorhini | 1 | 2002 | 81 | 0.010 |
Why?
|
| Body Constitution | 1 | 2002 | 26 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 411 | 0.010 |
Why?
|
| Infection Control | 1 | 2003 | 132 | 0.010 |
Why?
|
| Deoxyglucose | 1 | 2001 | 39 | 0.010 |
Why?
|
| Social Support | 1 | 2004 | 239 | 0.010 |
Why?
|
| Antirheumatic Agents | 1 | 2002 | 61 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2001 | 180 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 2001 | 147 | 0.010 |
Why?
|
| Cross Infection | 1 | 2003 | 159 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2001 | 117 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2004 | 361 | 0.010 |
Why?
|
| Anxiety | 1 | 2004 | 339 | 0.010 |
Why?
|
| DNA Replication | 1 | 2002 | 177 | 0.010 |
Why?
|
| Untranslated Regions | 1 | 2000 | 18 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 2002 | 89 | 0.010 |
Why?
|
| Arizona | 1 | 2000 | 10 | 0.010 |
Why?
|
| Vaccines, Combined | 1 | 2000 | 6 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2003 | 312 | 0.010 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2000 | 18 | 0.010 |
Why?
|
| Length of Stay | 1 | 2004 | 833 | 0.010 |
Why?
|
| Thyroxine | 2 | 1995 | 388 | 0.010 |
Why?
|
| Sick Leave | 1 | 2000 | 15 | 0.010 |
Why?
|
| Selection Bias | 1 | 2000 | 38 | 0.010 |
Why?
|
| Mass Vaccination | 1 | 2000 | 10 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2001 | 193 | 0.010 |
Why?
|
| Neuropeptides | 1 | 2000 | 116 | 0.010 |
Why?
|
| Adipocytes | 1 | 2001 | 170 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2000 | 7 | 0.010 |
Why?
|
| Emotions | 1 | 2004 | 377 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 2 | 1990 | 84 | 0.010 |
Why?
|
| Acute Disease | 2 | 1994 | 872 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 312 | 0.010 |
Why?
|
| Carrier State | 1 | 2000 | 40 | 0.010 |
Why?
|
| Cats | 2 | 1990 | 306 | 0.010 |
Why?
|
| Health Surveys | 1 | 2000 | 245 | 0.010 |
Why?
|
| Goiter | 1 | 1999 | 45 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1999 | 74 | 0.010 |
Why?
|
| Viremia | 1 | 1999 | 53 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 635 | 0.010 |
Why?
|
| Congenital Hypothyroidism | 1 | 1999 | 80 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 380 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 1999 | 198 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1999 | 796 | 0.010 |
Why?
|
| Speech-Language Pathology | 1 | 1997 | 5 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1997 | 141 | 0.010 |
Why?
|
| Transportation | 1 | 1997 | 20 | 0.010 |
Why?
|
| Fees and Charges | 1 | 1997 | 14 | 0.010 |
Why?
|
| Economic Competition | 1 | 1997 | 12 | 0.010 |
Why?
|
| Health Care Costs | 1 | 1999 | 255 | 0.010 |
Why?
|
| Efficiency, Organizational | 1 | 1997 | 55 | 0.010 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2000 | 292 | 0.010 |
Why?
|
| Sequence Tagged Sites | 1 | 1996 | 11 | 0.010 |
Why?
|
| Income | 1 | 1997 | 90 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1996 | 46 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2000 | 1791 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 1999 | 199 | 0.010 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 1996 | 25 | 0.010 |
Why?
|
| Leukemia | 1 | 1998 | 328 | 0.010 |
Why?
|
| Hemiplegia | 1 | 1995 | 17 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 1997 | 295 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1995 | 71 | 0.010 |
Why?
|
| Mice, Obese | 1 | 1995 | 49 | 0.010 |
Why?
|
| Sulfonylurea Compounds | 1 | 1995 | 68 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 1997 | 197 | 0.010 |
Why?
|
| Receptors, Glucocorticoid | 1 | 1996 | 144 | 0.010 |
Why?
|
| Jews | 1 | 1995 | 42 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 1995 | 87 | 0.010 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 1995 | 37 | 0.010 |
Why?
|
| Triiodothyronine, Reverse | 1 | 1995 | 32 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1995 | 297 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1995 | 37 | 0.010 |
Why?
|
| Maryland | 1 | 1994 | 46 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 1995 | 192 | 0.010 |
Why?
|
| Hemagglutination, Viral | 2 | 1984 | 4 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 175 | 0.010 |
Why?
|
| Medicaid | 1 | 1997 | 260 | 0.010 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 1994 | 58 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1995 | 1049 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 1996 | 338 | 0.010 |
Why?
|
| Genomic Library | 1 | 1993 | 33 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1993 | 73 | 0.010 |
Why?
|
| Karyotyping | 1 | 1993 | 257 | 0.010 |
Why?
|
| Cytosol | 1 | 1993 | 198 | 0.010 |
Why?
|
| Hemagglutination Tests | 1 | 1991 | 10 | 0.010 |
Why?
|
| Iodides | 1 | 1991 | 18 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 1991 | 40 | 0.010 |
Why?
|
| Autoradiography | 1 | 1990 | 69 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 271 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 1990 | 63 | 0.010 |
Why?
|
| Epinephrine | 1 | 1990 | 92 | 0.000 |
Why?
|
| Photometry | 1 | 1990 | 14 | 0.000 |
Why?
|
| Vision Tests | 1 | 1990 | 20 | 0.000 |
Why?
|
| Thrombin Time | 1 | 1989 | 4 | 0.000 |
Why?
|
| Prothrombin Time | 1 | 1989 | 19 | 0.000 |
Why?
|
| Partial Thromboplastin Time | 1 | 1989 | 17 | 0.000 |
Why?
|
| Fibrinogen | 1 | 1989 | 52 | 0.000 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1989 | 32 | 0.000 |
Why?
|
| Platelet Count | 1 | 1989 | 97 | 0.000 |
Why?
|
| Thyrotropin | 1 | 1991 | 311 | 0.000 |
Why?
|
| Thyroid Gland | 1 | 1991 | 281 | 0.000 |
Why?
|
| Triiodothyronine | 1 | 1991 | 362 | 0.000 |
Why?
|
| Light | 1 | 1990 | 297 | 0.000 |
Why?
|
| Collagen | 1 | 1990 | 306 | 0.000 |
Why?
|
| Immunochemistry | 1 | 1988 | 18 | 0.000 |
Why?
|
| Arylsulfotransferase | 1 | 1988 | 4 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1988 | 326 | 0.000 |
Why?
|
| Pennsylvania | 1 | 1986 | 101 | 0.000 |
Why?
|
| Apomorphine | 1 | 1984 | 10 | 0.000 |
Why?
|
| Rats, Mutant Strains | 1 | 1984 | 23 | 0.000 |
Why?
|
| Haloperidol | 1 | 1984 | 29 | 0.000 |
Why?
|
| Brain Chemistry | 1 | 1984 | 120 | 0.000 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1984 | 18 | 0.000 |
Why?
|
| Norepinephrine | 1 | 1984 | 174 | 0.000 |
Why?
|
| Hospitals, Psychiatric | 1 | 1983 | 26 | 0.000 |
Why?
|
| Dopamine | 1 | 1984 | 283 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1983 | 254 | 0.000 |
Why?
|
| Motor Activity | 1 | 1984 | 332 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1980 | 107 | 0.000 |
Why?
|
| Adaptation, Biological | 1 | 1977 | 90 | 0.000 |
Why?
|